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ABSTRACT
DISTRIBUTION AND EFFICACY OF CHEMOTHERAPEUTICS IN THE
TREATMENT OF PRECLINICAL BRAIN METASTASES OF BREAST
CANCER
Tori Terrell Hall
Brain metastases are a critical, life-threatening problem for women with advanced
metastatic breast cancer. Approximately 80% of women with disseminated central lesions
are unable to survive the first year after diagnosis. Despite the breakdown of the bloodbrain barrier, chemotherapeutics have limited penetration and distribution into brain
metastases and are unable to induce cytotoxicity in the tumor. Limiting the development
of new treatments for brain metastases of breast cancer, there are no commercially
available in vitro models available that accurately model, and mimic the functionality of,
the in vivo blood-tumor barrier (BTB). In an attempt to address the aforementioned
problem, the following connected, but independent aims were proposed and completed in
a novel microfluidic device: (1) Determine the permeability of three passive markers and
one subject to efflux, in blood-brain barrier (BBB) and BTB models (2) Determine if
trastuzumab crosses the BBB and BTB barrier in both in vivo and in vitro models (3)
Evaluate if the microfluidic BBB and BTB models are relevant and comparable to current
in vivo models. Further, based on the data presented herein, additional questions and trials
have evolved into an evolution of the current microfluidic chip, discussed in the final
chapter. This dissertation incorporates multiple innovative and complex experiments,
which suggest that the current microfluidic chip accurately portrays the BBB and BTB
when compared to the in vivo barriers, and is a readily available and rapid throughput
model for all cancer, as well as BBB, researchers.

Dedication
I would like to dedicate this work to Roxie Mae, Jaxson Don, Amelia Jo, and our
future little(s) that have yet to arrive. I entered graduate school to become the best version
of me I could be, and you guys push me towards that every single day. You are the
sunshine of my life, and the joys of my heart. I love each one of you more than words
could ever express, and I thank God for bestowing upon me the honor of being your
momma.

iii

Acknowledgements
First and foremost, I would like to sincerely thank my mentor and advisor, Dr.
Paul Lockman. Dr. Lockman, I am so thankful for the risk you took on me when you
offered me a position in your lab back in 2012. The ability to work with you over the last
five years has been such an incredible honor, and advanced my scientific career in
insurmountable ways. I want to thank you for allowing me to work on such a dynamic
and unique project, and for not allowing me to give up in the summer of 2015, when I
was pregnant with the twins and completely burnt out. The wisdom, mentorship,
guidance, and inspiration you provided to me on a daily basis allowed me the room to
improve and discover universal truths, as well as helped establish a solid foundation for
my professional and scientific development. Thank you for the countless times you
allowed me to sit in your office and cry and always making time to listen with your roll
of paper towels tucked away. I know I would not have been able to navigate graduate
school, each of my projects, two cross country moves, two pregnancies, three kids, and
establishing (and maintaining) my family, without the unyielding tenderness, support,
understanding and unprecedented patience you provided me over the last five years. The
relationship I have with you and Julie is one that I will forever cherish, and I look
forward to the continuation of that friendship as I take the next step of this journey.

Next I would like to acknowledge and thank each of my committee members for
their willingness to be a part of my committee and for their contribution to my
experiences throughout graduate school. Each of you have provided influential
suggestions that have helped guide each of the projects included in this dissertation, as
iv

well as my overall progression as a professional. Dr. Petros, thank you all for the
challenging questions, numerous discussions regarding translational research, and how
each of my projects would successfully translate to the clinic. The passion you exert for
patients has truly inspired me, and the support and faith you have invested within me has
encouraged me to uphold excellence in every aspect of my life and career. Dr. Callery,
thank you for providing me with such a strong platform of encouragement, and for the
many discussions we had in your office about school, work, life and such; there is no
doubt that your support has been a significant aid in my time at WVU. Dr. Huber, thank
you for your valuable contributions and suggestions regarding the blood-brain barrier and
permeability; your knowledge has undoubtedly helped form and aid in this dissertation.
Dr. Barr, thank you for your support, encouragement, open door, and willing availability
to sit and talk with me, regardless of the topic; your wisdom, knowledge, and guidance on
navigating motherhood, work, and happiness has been an invaluable source throughout
the last two years and I truly appreciate your insight.

To my lab mates, Dr. Chris Adkins, Afroz Mohammad, and Neal Shah, there is no
doubt that I have gained immense knowledge from each of you and your willingness to
aid in different parts of these dissertation. Chris, thank you for accepting me into the lab
(almost) 5 years ago. I could not have asked for a better senior graduate student to have
learned techniques, and lab demeanor from. You set an excellent example for Afroz and
I, and I hope to have passed along the foundation of the lab in such a way that benefits
Dr. Lockman to the max, as you did to me. Afroz, I will always cherish the last 4 years
and the friendship we share. Thank you for always being willing to drop whatever you
v

were doing at a moment’s notice, to come and assist in whatever I was doing, or needing
help with (even if it meant you and Neal staying up in the lab until 11 PM with me doing
ENDLESS serial dilutions of radiation!!). You are the epitome of what one would hope
to have in a lab mate and, most of all, a friend. You will always have a place to stay in
Texas J Neal, thank you for your sense of humor, your desire to learn, and your
camaraderie. You were alongside Afroz and I in many of the crazy things we endured (at
least for the last year and a half or so) and I thank you for your organization,
functionality, and crazy taste in music. It definitely made those long hours in the IVIS
more enjoyable. Thank you all for truly making the lab, and West Virginia, feel like
family.

I would also like to thank Dr. Mohamed Nounou for his immeasurable guidance,
the foundation of my my cell culture knowledge, and the countless phone calls and
emails helping me solve whatever technical issue I may have been having. Nounou, thank
you and Fatema, for your aid in the trastuzumab project. You will always be a part of my
family. To Jessica Griffith and Emma Dolan, thank you both for your hard work and your
assistance throughout your time in the lab. The contributions you both made have
impacted my work, and my life, in more ways than one. To Dr. Julie Lockman, thank you
for the fantastic job you did at teaching pharmacology at WTAMU. Had I not taken that
course with you, I truly don’t believe I would be where I am today. Thank you for your
passion for teaching, for loving me (and my kids) as fiercely as you have over the last 8
years, and for the many lunch dates we had leading up to my joining Dr. Lockman’s lab.
Your friendship helped me through a really rough time in my life, and I sincerely thank
vi

you for that. To Dr. Karen Martin, Dr. Amanda Ammer, Sarah McLaughlin, and Emily
Ellis, thank you for the morning coffee talks, the uncountable amounts of belly laughs,
and for the unyielding support in the animal and imaging facilities. You guys are the real
MVPs and without your contributions, there is no doubt that this work would not have
been possible. Mandy, 85% of this dissertation would NOT have happened had you not
helped me in troubleshooting the Sweptfield for months on end, and I thank you
tremendously for that.

To my incredible family, no amount of words could truly express the gratitude I
have for the amount of love and support you all have shown me throughout my time in
graduate school. I know the decision for us to move from the Texas panhandle to West
Virginia was a tough one to handle, but you each supported and pushed me to finish
strong and I am so grateful for that. Mom and Dad, I could not have asked for two better
role models. You both instilled in me the foundation to believe in myself, to reach for my
dreams and to never give up, and to above all keep God first. Your love, support, faith,
and example have unquestionably shaped who I am today and I cannot thank you enough
for that. This most certainly would not have been possible without your love and support.
To Buddy and Shawn, thank you for accepting me into your incredible family and for
loving me so fiercely. Without your immeasurable support and constant encouragement,
the last three years would not have been as easy as they were. To my sweet Nana and
Grandmommy, thank you both for the endless amounts of love you imparted on me
anytime we talked. You both are so much of who I am, and I am so grateful to have been
raised with such strong, female influences. I love you both more than I can say. I only
vii

wish Papa and Granddaddy were here to see this. To Lance, Lexie, Kody, Keri, Lyndsey,
and Lucas, thank you all for your witty humor, the perfect group texts, and the countless
prayers you guys have said on my behalf regarding any exam, qualifier, or presentation I
endured. I am so fortunate to have been blessed with such incredible siblings and
siblings-in-law.

To Pat, thank you for the (enormous amount of) emotional support you have
provided to me for the last 10 years. You are the other pillar in the foundation of my
being, and I have never ceased in thanking the Lord for placing you in my life. Thank
you for the constant prayers and unwavering support you have shown me. I love you
tremendously.

To my incredible, selfless, servant hearted, stud of a husband, Ryan, the past few
years have not been without their stresses, but you have never ceased in providing a
stress-free home full of laughter and joy. There were many times over the last year alone
that I wanted to give in, but you never stopped encouraging me to achieve all that I could.
I would not be pursing the career path that I am if I did not have the enormous amount of
support from you that you’ve relentlessly demonstrated over the course of our marriage.
Thank you for being my best friend, my favorite date, the one who makes me laugh like
none other, and my strongest supporter. You are the peace that calms my crazy and my
tangible grace. You make me a better person, and I feel so honored to be your wife.

viii

Finally, but most importantly, I would like to thank the Lord for the opportunity
and blessing I was given at WVU, and for the irreplaceable relationships I have made
along the way. I owe all that I am and have to God, and I pray to always reflect that in my
life and career.

“And let us not grow weary of doing good, for in due season we will reap, if we do not
give up.” Galatians 6:9

ix

TABLE OF CONTENTS
ABSTRACT ……………………………………………………………………………. ii
DEDICATION ..………………………………………………………………………. iii
ACKNOWLEDGMENTS ……………………………………………………………. iv
TABLE OF CONTENTS ……………………………………………………………... x
LIST OF FIGURES ………………………………………………………………..... xii
ABBREVIATIONS ………………………………………………………………… xiii
CHAPTER
1. INTRODUCTION …………………………………………………………... 1
1.1. Background ………………………………………………………… 1
1.2. Chapter Summaries …………………………………………………. 2
1.3. References …………………………………………………………... 6

2. MODELING THE BLOOD-TUMOR BARRIER; A
REVIEW OF THE MOST COMMON IN VITRO
DEVICES ……………………………………………………..…...…… 9
2.1. The Blood-Brain Barrier ……………………………..……………... 9
2.2. The Blood-Tumor Barrier ………………………………………..... 12
2.3. In Vitro Models ……………………....………………………..…... 12
2.4. Static Model: Transwells and Their Limitations…….………..…… 16
2.5. Microfluidic Models ……………...……………………………..… 17
2.6. References ……………..…………………………………………... 27

3. PERMEABILITY ACROSS THE BLOOD-BRAIN
x

BARRIER AND BLOOD-TUMOR BARRIER; A
NOVEL IN VITRO MODEL ON A CHIP ………………………..…. 40
3.1. Introduction …………………………………………………...…… 40
3.2. Materials and Methods …………………………………………….. 43
3.3. Results ………………………………………...…………………… 48
3.4. Discussion …………………………………………………………. 51
3.5. References …………………………………………………………. 63

4. TRASTUZUMAB EFFICACY IN AN IN VIVO
AND IN VITRO MODEL OF BRAIN METASTASES
OF BREAST CANCER ………………………………………………. 74
4.1. Introduction ………………………………………………………... 74
4.2. Materials and Methods …………………………………………….. 77
4.3. Results ……………………………………………………………... 84
4.4. Discussion …………………………………………………………. 86
4.5. References ………………………………………………………..... 94

5. CONCLUSIONS AND FUTURE DIRECTIONS ……………………… 103
5.1. Chapter Conclusions ……………..………………………………. 103
5.2. Future Directions ………………………………………………… 105
5.3. References ……………………………………...………………… 116

CURRICULUM VITAE ……………………………………….……………………. 117

LIST OF FIGURES
xi

3.1: Microfluidic chip schematic and methods ………………………………………… 55
3.2: 3-D confocal image of DAPI labeled HUVECs in apical chamber ……………..… 57
3.3: Diffusion rates of different sized MW tracers in the same model ………………… 58
3.4: Representative time-lapse images showing passive diffusion of Free
TRD from the outer to the central compartment ………………………………….. 59
3.5: Linear central compartment accumulation of different tracers in the
BBB and BTB microfluidic chip models …………………………………………. 60
3.6: Rhodamine-123 permeability with and without inhibitors in BBB and
BTB models ………………………………………………………………..……… 61
4.1: Mechanism of trastuzumab movement …………………………………………… 90
4.2: The distribution of radiolabeled 125I –trastuzumab in various body
organs, and in normal and tumor brain tissues ……………………………………. 91
4.3: Heterogeneous and limited distribution of 125I-trastuzumab in
preclinical brain metastases of breast cancer model ……………………………… 92
5.1: Microfluidic BTB device overall modifications …………………………………. 110
5.2: Re-engineering of the BTB microfluidic device to allow
for real-time TEER measurements ………………………………………………. 111
5.3: Port volumes of the current microfluidic device ………………………………… 112
5.4: Proposed redesign for increased recovery port volumes of
the microfluidic device …………………………………………………………... 113
5.5: Tumor cell extravasation ………………………………………………………… 114
5.6: Isolation of different cells of varying metastatic potential ………………………. 115

xii

ABBREVIATIONS
CNS – Central Nervous System
BTB – Blood-tumor barrier
BBB – Blood-Brain Barrier
TEER – Transendothelial Electrical Resistance
PDMS – Polydimethylsiloxane
bEnd3 – Brain endothelial cells
PC – Polycarbonate
ACM – astrocyte-conditioned medium
p-gp – p-glycoprotein
Rho123 – Rhodamine-123
HBMEC – human brain microvascular endothelial cells
Free TRD – Sulforhodamine 101 Acid Chloride
TRD 3 kDa – Texas Red 3000 MW Dextran
TRD 70 kDa – Texas Red 70,000 MW Dextran
HUVECs – Human Umbilical Vein Endothelial Cells
EBM-2 – Endothelial Basal Medium – 2
kin – Unidirectional uptake transfer constants
t-Rho123 – fluorescent trastuzumab-Rho123
TRD 625 Da – Texas red conjugated 625 MW dextran
eGFP – enhanced green fluorescent protein
IP – intraperitoneal
PDXs – patient derived xenografts
xiii

CHAPTER 1
INTRODUCTION

1.1 Background
One of the most critical factors concerning advanced stage breast cancer is the
incidence of brain metastases. The incidence of brain metastases has risen significantly
over the past 12 years (Carey, Ewend et al. 2004, Clayton, Danson et al. 2004, Lin,
Bellon et al. 2004, Tham, Sexton et al. 2006, Smid, Wang et al. 2008, Olson, AbdelRasoul et al. 2013), probably due to successful treatements of the primary disease,
leading to longer survival times and allowing for an increase in peripheral disease to
occur. In advanced stage breast cancer, 10-16% of patients develop brain metastases
(Palmieri, Smith et al. 2006) making breast cancer the second most common cause of
metastatic brain tumors after lung cancer (10–25%) (Steeg, Camphausen et al. 2011, Lin
2013, Yeh, Yu et al. 2015). Once a clinically detectable brain metastases is discovered
and the patient becomes symptomatic, median survival is approximately 4 months
(Colzani, Liljegren et al. 2011) with less than 2% of women surviving two years postdiagnosis (Zimm, Wampler et al. 1981).

Despite the increased incidence, and the poor survival prognosis, treatment
options are limited. Once diagnosed with a central nervous system (CNS) metastases,
traditional treatment options have included radiation, surgery, and adjunctive systemic
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therapy. With regard to chemotherapy, inadequate drug delivery to tumors is because of
poor penetration of drugs across the blood-tumor barrier (BTB) (Lockman, Mittapalli et
al. 2010). This could be due to both poor permeability and an inadequate distribution to
cross the BTB, or to the active efflux of the chemotherapeutics due to efflux transporters
along the BTB and the individual tumor cells, actively removing the drugs from the brain
parenchyma and back into the bloodstream once they have successfully crossed the BTB
(Adkins, Mittapalli et al. 2013). Preclinical development of novel drugs to address these
issues ultimately fail in clinical trials due to the unavailability of in vitro models that
successfully predict or mimic the in vivo BTB.

The premise of this dissertation builds upon this significant body of literature
demonstrating a failure of current chemotherapy regimens in the treatment of brain
metastases of breast cancer due to poor distribution across the BTB. The specific aims of
this dissertation were to: (1) Determine the permeability of three passive markers and one
subject to efflux, in blood-brain barrier (BBB) and BTB models (2) Determine if
trastuzumab crosses the BBB and BTB barrier through both in vivo and in vitro models
(3) Evaluate if this microfluidic BBB and BTB models are relevant and compatible to
current in vivo models.

1.2 Chapter Summaries
1.2.1 Chapter 2
There are multiple preclinical in vitro models available, however the limitations
of each result in models that do not adequately mimic the in vivo BBB and BTB. In this
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chapter we thoroughly review the current static and microfluidic in vitro BBB and BTB
devices, as well as each of their limitations in preclinical research.

1.2.2 Chapter 3
The lack of translatable in vitro BTB models creates challenges in the
development of drugs to treat tumors of the CNS and our understanding of how the
vascular changes at the BBB in the presence of a tumor. In this study, we
characterize a novel microfluidic model of the BTB model (and BBB model as a
reference) that incorporates flow that induces shear stress on endothelial cells. Cell
lines utilized include human umbilical vein endothelial cells co-cultured with CTXTDR2 rat astrocytes (BBB) or Met-1 metastatic murine breast cancer cells (BTB).
Cells communicated across microfluidic compartments via a porous interface. We
characterized the device by comparing permeability of three passive permeability
markers, and one marker subject to efflux. The permeability of Sulforhodamine 101
was significantly (p < 0.05) higher in the BTB model (13.1 ± 1.3 X 10-3, n=4) than the
BBB model (2.5 ± 0.3 X 10-3, n=6). Similar permeability increases were observed in
the BTB model for molecules ranging from 600Da to 60kDa. The function of p-gp
was intact in both models and consistent with recent published in vivo data.
Specifically the rate of permeability of Rhodamine-123 across the BBB model (0.6 ±
0.1 X 10-3, n=4), increased 14-fold in the presence of verapamil (14.7 ± 7.5 X 10-3,
n=3) and eight fold with the addition of cyclosporine A (8.8 ± 1.8 X 10-3, n=3).
Similar values were noted in the BTB model. The dynamic microfluidic in vitro BTB
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model is a novel commercially available model that incorporates shear stress, and
has permeability and efflux properties that are similar to in vivo data.

1.2.3 Chapter 4
Drug and antibody delivery to brain metastases has been highly debatable in the
literature. The BTB, thought to be somewhat more permeable than the BBB, has shown
to exhibit highly functioning efflux transporters and barrier functions, limiting delivery of
these targeted therapies. The purpose of this study was to test the permeability of (1) I125trastuzumab in an in vivo, and (2) fluorescent trastuzumab-Rho123 (t-Rho123) in a novel
in vitro BBB and BTB brain metastases of breast cancer model. In vivo: Human MDAMB-231-HER2+ metastatic breast cancer cells were grown and maintained under static
conditions. Cells were harvested at 80% confluency and prepped for intracardiac
injection into 20 homozygous female NuNu mice. In vitro: Human umbilical vein
endothelial cells were grown and maintained under shear stress conditions, co-cultured
with CTX-TDR2 rat brain astrocytes (BBB) or Met-1 metastatic HER2+ murine breast
cancer cells (BTB), grown and maintained under static conditions, across a porous
interface in the outer and central compartments, respectively. Tissue distribution of 125Itrastuzumab revealed only ~3% of injected dose reached normal brain, with ~5% of
injected dose reaching the brain tumor. No clear correlation was observed between size of
metastases and the amount of 125I-trastuzumab localized in vivo. This heterogeneity was
paralleled in vitro, where the distribution of t-Rho123 from the outer chamber to the
central chamber of the microfluidic device was qualitatively and quantitatively analyzed
over time. The rate of t-Rho123 linear uptake in the BBB (0.27 ± 0.33 X 104) and BTB
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(1.29 ± 0.93 X 104) showed to be significantly greater than 0 (p < 0.05). The BTB
devices showed significant heterogenetic tendencies, as seen in in vivo. This study is one
of the first studies to measure antibody movement across the blood-brain and bloodtumor barriers, and demonstrates that, though minute, trastuzumab does cross the bloodbrain and blood-tumor barriers.

1.2.4 Chapter 5
The conclusions of each chapter are discussed as well as the results of chapters 3
and 4, in the form of modifications to the microfluidic device. These modifications were
developed due to complications and failed experiments within the projects of chapter 3
and chapter 4. These modifications will result in improvements of different aspects of the
device, leading to the future directions of this dissertation.
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CHAPTER 2
MODELING THE BLOOD-TUMOR BARRIER; A REVIEW OF THE
MOST COMMON IN VITRO DEVICES

2.1 The Blood-Brain Barrier
2.1.1 Cellular Function
The blood-brain barrier (BBB) is a highly controlled and strictly regulated
complex network of brain microvessels. This barrier is the primary protective interface
for the brain that functionally restricts ions, molecules, toxins and drug movement from
blood to the brain parenchyma (Almutairi, Gong et al. 2016). The protective nature of the
BBB is due in part to the multicellular system (neurovascular unit) that forms it,
consisting of microvascular brain endothelial cells surrounded by astrocytic foot
processes, pericytes, neurons, and microglia (Wolff, Antfolk et al. 2015). The first, and
primary cellular unit of the neurovascular unit are the microvascular brain endothelial
cells. These specific endothelial cells are noted for their absence of fenestrae and the
presence of a continuous basement membrane (shared with pericytes) (de Boer and
Gaillard 2006). These two components are key elements to the highly restrictive nature
across microvascular endothelial cells when compared to normal endothelial cells. Brain
microvascular endothelial cells also express a higher than normal amount of tight
junctions as well as limited pinocytic vesicular transport (Abbott, Patabendige et al. 2010,
Wolff, Antfolk et al. 2015).
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The next cellular structure of the neurovascular unit family are the astrocytes.
Found only in the brain, these cells provide much needed biochemical support to the
BBB through contact to the microvascular brain endothelial cells with their multiple foot
processes (Taber and Hurley 2008). This biochemical support has been previously
studied, and has well established the importance of astrocytes to the integrity of the BBB
(Abbott 2002) and paracellular movement (Zheng, Aschner et al. 2003), as well as the
secretion of various factors required for successful BBB function (Janzer and Raff 1987,
Siddharthan, Kim et al. 2007, Colgan, Collins et al. 2008).

Pericytes are the third cellular structure, and they cover approximately 22%-33%,
or one fifth to one third, of the basolateral portion of a capillary (Kim, Tran et al. 2006).
Pericytes have multiple functions; they have been shown to induce the polarity of
astrocytes leading to a tightening of the BBB (Allt and Lawrenson 2001), affect the
integrity of the BBB through direct contact with the endothelial cells (Hayashi, Nakao et
al. 2004), and may play a role in angiogenesis (Daneman, Zhou et al. 2010). Pericytes
also inhibit the expression of molecules known to increase vascular permeability
(Daneman, Zhou et al. 2010), while a deficiency of pericytes has been linked to an
increase in permeability of the BBB (Armulik, Genove et al. 2010).

The last two cells related to the neurovascular unit composing the BBB are
neurons and microglia. Neurons, the main functional cells of the brain, communicate
through different chemical and electrical signals. These signals rely on the movement of
small ions, which aids in the overall maintenance of stable membrane potentials (Abbott
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2013). The presence of neurons has also been shown to increase the integrity of the BBB
(Minami 2011), which helps maintain the homeostasis of the brain, and protect the brain
from the influx and efflux of ions. Microglia, the final member of the neurovascular unit,
are found in the perivascular space and are the immune cells of the central nervous
system (CNS), meaning they simply clear away debris and apoptotic cells from the brain
(Sumi, Nishioku et al. 2010).

2.1.2 Restrictions and Permeability
Within the neurovascular unit, tight junctions at the level of the endothelia play a
major role in the protective nature of the BBB. Tight junctions are a hallmark of the
BBB, and are composed of claudins, occludins, and junctional adhesion molecules. These
junctions seal the microvascular endothelial cells together, creating a physical barrier that
aids in the regulation of drugs, oxygen, nutrients, ions and pathogens from systemic
circulation to the brain (Petty and Lo 2002). Tight junctions also restrict paracellular
transport, or the movement through the intracellular space between cells. Paracellular
transport is a passive pathway and relies on concentration gradients and permeability,
causing it to be a slow method of transport (Pardridge 1999). Due to tight junctions
tightly restricting the paracellular movement between endothelial cells, an alternative
mechanism to circumvent the BBB is through transcellular transport. Transcellular
pathways, or the movement through a cell, are energy dependent and substrate specific
(Mager, Meyer et al. 2016). For example, lipophilic molecules can cross the BBB
through transendothelial receptor-mediated transport (Schinkel 1999, Vorbrodt and
Dobrogowska 2003, Roberts, Black et al. 2008, Abbott, Patabendige et al. 2010).
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2.2 The Blood-Tumor Barrier
Once a metastatic tumor cell extravasates from the primary tumor location, it
enters the bloodstream and travels to a secondary location, where it embeds and begins to
establish its own blood supply (Carmeliet and Jain 2000, Talmadge and Fidler 2010,
Eichler, Chung et al. 2011). This process causes a change in the barrier, from the bloodbrain barrier to the blood-tumor barrier (BTB). A tumor’s blood supply may develop
through a couple of mechanisms: vasculogenesis, angiogenesis, and co-option being the
main forms. During development, new blood vessels are formed in a process called
vasculogenesis. Tumor cells have been observed mimicking endothelial cells and forming
vascular vessels themselves through the use of cancer stem cells or tumor initiating cells
(Krishna Priya, Nagare et al. 2016). Angiogenesis is the secretion of vascular endothelial
growth factor by the tumor cell to form sprouts from existing blood vessels (Carmeliet
and Jain 2000, Folkman 2007, Carmeliet and Jain 2011). Tumor cells can also grow
along an existing blood vessel instead of sprouting new blood vessels in a mechanism
known as co-option (Frentzas, Simoneau et al. 2016). After a tumor establishes a blood
supply, the only thing left is to grow. Tumor permeability, or the leakiness of a tumor, is
affected by how many fenestra are present in the BTB, and the spatial distribution of, or
distance between, the tumor vasculature.

2.3 In Vitro Models
2.3.1 Basic Premise
The best way to study molecular transport across the BBB is in vivo, or studies in
the animal’s natural environment, however only ~50% of these results are translational to
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human (Perel, Roberts et al. 2007). Since in vivo studies are difficult and expensive, in
vitro models are utilized. In vitro BBB models should, ideally, mimic the structural and
functional properties of the in vivo BBB and meet the following four requirements: 1)
Tight junction expression should result in a very restricted barrier. 2) Correct placement
(luminal vs. abluminal) of influx and efflux transporters, as well as the functionality of
each transporter compared to the in vivo BBB (Roberts, Black et al. 2008). 3)
Permeability across the BBB and BTB should be comparable to in vivo (Adkins,
Mittapalli et al. 2013). 4) Replication of shear stress and vascular flow (Ballermann,
Dardik et al. 1998, Tarbell 2010, Cucullo, Hossain et al. 2011).

Shear stress and vascular flow dramatically alters the morphology of endothelial
cells when compared to static cells (Cucullo, Hossain et al. 2011, Prabhakarpandian,
Shen et al. 2013, Deosarkar, Prabhakarpandian et al. 2015) (SynVivo Chapter 3). Without
the added shear stress of vascular flow, endothelial cell morphology is described as flat
and small, with an increased presence of endocytic vesicles, microfilaments and
clatherin-coated pits (Ballermann and Ott 1995). However, through the addition of
vascular flow, shear stress alters the endothelial cellular morphology through the
elongation and increase in size of the endothelia, as well as a decrease in the presence of
endocytic vesicles, microfilaments, and clatherin-coated pits. There is documented
evidence also showing a correlated increase in the strength of tight junctions between
endothelial cells with the addition of shear stress (Collins, Cummins et al. 2006, Colgan,
Ferguson et al. 2007, Siddharthan, Kim et al. 2007).
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Every in vitro model includes the same basic parameters: barrier cells,
extracellular matrix, and a brain microenvironment (Stanimirovic, Bani-Yaghoub et al.
2015). The barrier cells are grown on semipermeable membrane dividing the basolateral
and apical compartments, which are located on one side (apical) of the extracellular
matrix. The extracellular matrix is located on a semipermeable membrane, which
separates the brain microenvironment (basolateral) and the barrier cells. When studying
permeability, drugs are placed in the apical compartment and the movement is measured
in the basolateral compartment, and studied over time. These models have previously
been studied in a 6-96 well format, and can be miniaturized through the use of
microfluidics to increase throughput and mimic shear stress as seen in vivo.

2.3.2 Cell Culture Options
In any in vitro system, there is the option of monoculture, co-culture, or triple
culture of the cells (Wolff, Antfolk et al. 2015). One of the most widely and easily used
in vitro systems is a monoculture system. In this system, the only cells used are
endothelial cells, grown on the apical side of the model, occasionally with the addition of
astrocyte-conditioned media, which has been shown to increase barrier function
(Siddharthan, Kim et al. 2007). However, despite having only one cell type, the absence
of astrocytes makes this model undesirable due to the vast amount of data showing the
importance of astrocytes to the integrity of the BBB (Abbott 2002, Abbott, Patabendige
et al. 2010, Abbott 2013). The next step in the in vitro model system is the co-culture
system: contact co-culture or noncontact co-culture. Depending on the type of model, the
transendothelial electrical resistance (TEER) will vary. TEER is a quantitative technique
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used to measure the tightness of the seal between endothelial cells (created by tight
junctions) and is a good indicator of the functionality of the BBB. The higher the TEER
value, the stronger the integrity of the barrier is thought to be. In a contact co-culture
system, endothelial cells are grown as in the monoculture model, with
astrocytes/pericytes/neurons grown on the bottom of the porous membrane (if in a
transwell) or in the basolateral chamber, where they are able to have direct contact with
the endothelial cells. Through direct contact with the secondary cells, the TEER values
for endothelial cells have been shown to increase by upwards of nine times higher, in
comparison, to the monoculture model (Gaillard, Voorwinden et al. 2001, Nakagawa,
Deli et al. 2009).

In contrast, a noncontact co-culture system is where the
astrocytes/pericytes/neurons are grown on the bottom of the 6-96 well plate, not in direct
contact with the endothelial cells. Morphological, chemical, and biological changes can
be observed due to the chemical gradient, with TEER values reportedly increased by a
factor of 2 in comparison to the monoculture model (Nakagawa, Deli et al. 2009). The
last, most complicated, model is the triple culture. There are a couple of options with this
model: 1) Endothelial cells are in direct contact with astrocytes and indirect contact with
neurons, showing a 35.9% increase in TEER when compared to monoculture (Xue, Liu et
al. 2013). 2) Endothelial cells are in direct contact with pericytes and indirect contact
with astrocytes, where an eight-fold increase in TEER is observed in comparison to the
monoculture model (Nakagawa, Deli et al. 2007).
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2.4 Static Model: Transwells and Their Limitations
When choosing an in vitro model, the desire is to find a model that cultures pure
cell types resulting in high TEER values with low permeability. There are a couple
options when choosing an in vitro BBB/BTB model: static or microfluidic models.
Transwells are the most widely used and commercially available static in vitro models to
study diffusional movement across endothelia are transwell systems. Briefly, it consists
of an upper chamber with endothelia grown on top of a porous membrane, which resides
above a lower chamber containing astrocytes/neurons for a blood-brain barrier (BBB)
model and cancer cells for a BTB model (Bicker, Alves et al. 2014, Czupalla, Liebner et
al. 2014, Srinivasan, Kolli et al. 2015, Helms, Abbott et al. 2016). Permeation of
molecules and or cells is evaluated by calculating accumulation/distribution between
compartments.

The transwell model has limitations that result in calculation errors in drug
movement, as well as increased apparent permeability rates due to the endothelia (upper
chamber) having gaps between cells near the insert edge (Noseda, Chang et al. 2004,
Santaguida, Janigro et al. 2006), and because of the lack of flow associated sheer stress
which decreases tight junction formation (Prabhakarpandian, Shen et al. 2013, Czupalla,
Liebner et al. 2014, Deosarkar, Prabhakarpandian et al. 2015, Helms, Abbott et al. 2016).
Another limitation is the ten-fold difference in drug diffusion calculations when
compared to “proportional” in vivo measurements due to the presence of an unstirred
water layer above the endothelial surface. This unstirred water layer results in increased
permeability for hydrophilic drugs and decreased permeability for lipid soluble drugs
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(Barry and Diamond 1984, Noseda, Chang et al. 2004, Prabhakarpandian, Shen et al.
2013, Czupalla, Liebner et al. 2014, Deosarkar, Prabhakarpandian et al. 2015).

2.5 Microfluidic Models
Microfluidic devices are still early in the BBB field and aren’t as widely used as
transwells due to their price, lack of commercial availability, and issues for researchers to
master (Stanness, Guatteo et al. 1996, Lippmann, Azarin et al. 2012). Despite not being
as well used, the basic premise for most microfluidic devices is still the same. As with
transwells, endothelial cells are co-cultured in a luminal (apical) compartment with
astrocytes, or the secondary cells of choice, are seeded on the basolateral side of the
lumen. After all cells have been established and allowed to grow in static conditions,
vascular flow is exerted in the apical chamber for a set amount of time, and permeability
studies are allowed to commence through the flow of tracer through the apical chamber
with samples taken from the basolateral chamber.

In recent years static co-culture has begun to fall by the wayside with the advent
of more physiologically relevant models. There has been a great deal of work in the
realms of microfluidics, or lab-on-a-chip technologies, in order to address some of the
known shortcomings of other in vitro models. The push to establish a reliable and
replicable microfluidic BBB has quickly produced a wide variety of models, most of
which incorporate consistent flow in order to promote the expression of tight junctions in
cultured endothelial cells and more closely mimic the in vivo BBB, though these models
are not without their own difficulties and shortcomings (van der Helm, van der Meer et
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al. 2016). To characterize these models, investigators employ similar quantifying
methods as those used to characterize transwells and other static cultures. These methods
include: TEER, immunofluorescent staining of tight junctions, cell viability assays, and
measurement of the permeability of various compounds, which may then be compared to
in vivo values and other static in vitro models (Lockman, Mittapalli et al. 2010, Adkins,
Mittapalli et al. 2013, Thomsen, Burkhart et al. 2015). For this review, we have selected a
number of models representing the wide diversity of approaches to creating a
microfluidic BBB.

2.5.1 Stacked Compartmental Designs
One of the first viable models of microfluidic tissue culture developed specifically
to model the BBB was developed by Booth and Kim in 2012 (Booth and Kim 2012).
Their model utilized stacked polydimethylsiloxane (PDMS) culture chambers separated
by a perforated membrane. These separate chambers allowed for separate culture of
astrocytes (C8D1A) and brain endothelial cells (bEnd3), as well as their biochemical
communication through the membrane, which has also been previously observed with
transwell models (Booth and Kim 2012). Electrodes were incorporated to allow for
TEER measurements. Nearly all endothelial cells seeded in the device remained viable
and expressed tight junctions after 3 days under continuous flow of 2.6 mL min-1 (Booth
and Kim 2012). Their static control, traditional transwells, exhibited TEER values around
25 Ω cm2, and a significant increase in TEER when dynamic flow was incorporated in
their chip model, over 250 Ω cm2 (Booth and Kim 2012). They also showed a significant
improvement in TEER values from a bEnd3 monolayer in their chip device, nearly 175 Ω
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cm2, to devices in co-culture with steady-state TEER values at more than 250 Ω cm2
(Booth and Kim 2012).

Many other models utilize PDMS superstructure because it is optically
transparent, inexpensive, can be adapted to virtually any 3D-printed silicon cast, and is
relatively expedient in production, as a 10:1 mixture of base to curing agent can cure in
approximately 1h (Yeon, Na et al. 2012, Achyuta, Conway et al. 2013, Griep, Wolbers et
al. 2013, Prabhakarpandian, Shen et al. 2013, Brown, Pensabene et al. 2015, Cho, Seo et
al. 2015, Deosarkar, Prabhakarpandian et al. 2015, Sellgren, Hawkins et al. 2015, Wang,
Khafagy el et al. 2016). In 2013, Achyuta et al. also developed a vertically stacked
PDMS compartment device. However, their approach required the separate culture of
RBE4 endothelial and primary rat cortical cells in their respective chambers before
stacking the components brought them into a co-culture environment, in which the flow
over the endothelial cells was approximately 17 µL min-1 (Achyuta, Conway et al. 2013).
The TEER of the barriers in these devices could not be measured, as no electrodes were
incorporated into the device, but the in vitro BBB displayed appropriate physiological
responses to TNFα stimulation, namely increased permeability to a 3kDa AlexafluorTMconjugated dextran (Achyuta, Conway et al. 2013). Endothelial cells were also confirmed
to express tight-junction protein ZO-1, which was elevated in the presence of astrocyte–
conditioned medium (ACM) (Achyuta, Conway et al. 2013).

One of the most recent stacked PDMS devices was developed by Sellgren et al. in
2015. They also cultured cells in stacked PDMS chambers separated by 0.4 µm porous
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membranes of two different materials: nanopourous Teflon and polycarbonate (PC).
Rather than seeding their C8D1A astrocytes on one side of the membrane directly, they
suspended the cells in a collagen matrix and injected them into the device before seeding
the bEnd3 cells on the opposite side of the membrane (Sellgren, Hawkins et al. 2015).
The endothelial cell chamber was 150 µm in diameter, the size of a vessel much larger
than human brain capillaries, which average approximately 10 µm in diameter (Wong,
Ye et al. 2013). However, they still achieved near physiological shear stress at 5 dyn cm-2
with a flow rate of 120 µl min-1. Their model displayed distinct tight junction expression
through the staining of claudins, and also a significantly tighter barrier than those
observed in static transwell cultures, and the two membrane materials were comparable
(Sellgren, Hawkins et al. 2015).

Other stacked devices have been produced, and though they fail to recapitulate the
cylindrical shape of capillaries and the brain tissue surrounding them, some have made
very promising strides in the improvement of in vitro BBB models. Wang et al. fabricated
a device using a 3D printer to deposit Objet VeroClear photopolymer to create a set of
stacked compartments for cell culture and media storage (Wang, Khafagy el et al. 2016).
Their model utilized a rocking table rather than a perfusion pump to move media across
the surface of BMECs differentiated from human pluripotent stem cells, which were
maintained in co-culture with primary rat astrocytes (Wang, Khafagy el et al. 2016).
Without the magnitude of shear stress induced in other models to promote formation of
tight junctions, their chip devices still maintained TEER values of 3000 Ω cm2 (Wang,
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Khafagy el et al. 2016), some of the closest to in vivo values seen in an in vitro model,
which they credit to . This may be due to the origin of their cells, which is unique.

2.5.2 Horizontal Layouts
Another set of PDMS models have been designed with a horizontal layout. A
number of microfluidic models have been developed using devices produced by SynVivo
Corporation. Prabhakarpandian et al. created their SymBBB using a PDMS
superstructure mounted to a glass microscope slide (Prabhakarpandian, Shen et al. 2013).
It was seeded with rat brain endothelial cells (RBE4) and perfused with ACM at a rate of
0.1 µl min-1. Bifurcated apical chambers were separated from a central basolateral
chamber by a 100 µm section of PDMS perforated with 3µm gaps to allow for passive
diffusion (Prabhakarpandian, Shen et al. 2013). Though their chip did not include
electrodes for TEER evaluation, they could be imaged to show real-time diffusion and
permeability of fluorescent tracer (Prabhakarpandian, Shen et al. 2013). They assessed
transwell permeability of 3-5kDa FITC-dextran over time and compared it to their
device, showing a significant decrease in permeability in the microfluidic model both
with and without ACM (Prabhakarpandian, Shen et al. 2013). It was also observed that
cells cultured in their device with ACM exhibited normal P-glycoprotein (p-gp) efflux of
Rhodamine-123 (Rho123), and an increased permeability of Rho123 through the RBE4
endothelium in the presence of the p-gp inhibitor, verapamil (Prabhakarpandian, Shen et
al. 2013).
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An additional set of experiments by Deosarkar et al. demonstrated the
development of a neonatal rat BBB in another variation of a SynVivo microfluidic chip.
The device contained two separate apical chambers and a circular central basolateral
chamber, and these chambers were separated by a section of PDMS with the same 3µm
gaps as the aforementioned device (Deosarkar, Prabhakarpandian et al. 2015). The
devices were seeded with primary neonatal rat astrocytes and primary neonatal Rat brain
endothelial cells which, after attachment, were maintained under a constant flow of 0.01
µl min-1 (Deosarkar, Prabhakarpandian et al. 2015). To assess permeability, 40kDa Texas
Red dextran was perfused into the device at a rate of 0.2 µl min-1 for 90 minutes. They
performed these experiments as well as ICC on cells in a variety of environments (with
primary astrocytes, with ACM, and with primary neonatal rat brain endothelial cells
alone) and found a significant decrease in permeability and an increase in the expression
of tight junction protein ZO-1, which was dependent on the presence of astrocytes or
ACM (Deosarkar, Prabhakarpandian et al. 2015). Barrier tightness was also assessed
through electrical resistance and, again, increased with the presence of astrocytes and
ACM (Deosarkar, Prabhakarpandian et al. 2015). However, these values cannot, as of
now, be compared to TEER values from transwells or other models, due to the novel
methodology and equipment used to acquire the measurements (Deosarkar,
Prabhakarpandian et al. 2015).

2.5.3 Hollow Fibrous Cellular Supports
Another model, produced by Herland et al. in 2016, utilizes a combination of
PDMS super structure and a hollow tube of collagen fibers for cell support. Within what
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amounts to a simple PDMS box, they used a collagen matrix with suspended human
astrocytes to form a cylindrical vessel (Herland, van der Meer et al. 2016). They then
seeded human pericytes in two stages, flipping the device over in each stage to form a
full cylindrical monolayer of the cells, and followed with the seeding of human brain
microvascular endothelial cells (HBMEC) (Herland, van der Meer et al. 2016). In this
way, they created a softer, more physiologically relevant structure than other PDMS
models while also incorporating all three structural components of brain microvessels
(Herland, van der Meer et al. 2016). At a flow of 120 µL min-1, they achieved a shear
stress of 1 dyne cm-2, which is low in comparison to physiological conditions.

They measured barrier tightness using 3 kDa-Alexa488 Dextran diffusion, as
TEER electrodes could not be reliably incorporated into their collagen gels (Herland, van
der Meer et al. 2016). They also assessed the inflammatory response of the in vitro
vessels to TNFα and stained for tight junction proteins (Herland, van der Meer et al.
2016). They then compared their dynamic model to transwells seeded with the same
cells. Though their study focused on the particular effects of the presence of astrocytes or
pericytes, rather than the creation of a physiologically relevant model with a sufficiently
tight barrier, they did observe distinct expression of tight junctions (Herland, van der
Meer et al. 2016). They also found that their model responded differently to inflammation
than transwells, with the synthetic vasculature exhibiting a lower fold-increase in
inflammatory cytokines released after stimulation with TNFα (Herland, van der Meer et
al. 2016).
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Other models have built on a variety of materials for cell support. Cucullo et al.
built upon previous capillary models (Cucullo, McAllister et al. 2002) and also used two
sets of hollow polypropylene fibers housed in sealed chambers and connected by gas
permeable silicon tubing (Cucullo, Hossain et al. 2013). The abluminal surface of each
hollow fiber was coated with fibronectin to promote endothelial cell adhesion, and the
outer surface was coated with poly-D-lysine to allow for the attachment of astrocytes
(Cucullo, Hossain et al. 2013). In one chamber, which contained n=3 hollow fibers,
HBMECs were seeded on the abluminal surface of each hollow fiber, and human
astrocytes were seeded on the external surface (Cucullo, Hossain et al. 2013). In the other
chamber, hollow fibers were seeded with HBMECs and human brain vascular smooth
muscle cells rather than astrocytes (Cucullo, Hossain et al. 2013). These two chambers
were sealed and connected with silicon tubing to a reservoir of media and a pulsatile
pump, which delivered a flow of media which was gradually increased from a low shear
stress of 1 dyne cm-2 to what was comparable to a physiologically relevant blood pressure
(80-300mmHg)(Cucullo, Hossain et al. 2013).

This complex model of brain vasculature was then characterized by a variety of
experiments: TEER, molecular permeability assays, response to a hyperosmolar agent,
and the determination of metabolic activity (Cucullo, Hossain et al. 2013). TEER values
achieved by this system approached 800 Ω cm2 in the capillary component, whereas the
venule chamber did not achieve TEER above 250 Ω cm2(Cucullo, Hossain et al. 2013).
They measured permeability of Diazepam, phenytoin, and sucrose, showing a greater
permeability of each of these molecules in the venule segment in comparison to the
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capillary compartment, an observation consistent with in vivo physiology (Cucullo,
Hossain et al. 2013). When exposed to a hyperosmolar agent, in this case 1.6M mannitol,
which is sometimes used to increase the permeability of chemotherapeutics, the agent
induced same opening of the in vitro vascular model as has been observed in vivo
(Cucullo, Hossain et al. 2013). Finally, their bioenergetic assessment revealed that the
capillary segment favored aerobic respiration while the venule segment, which was
exposed to lower shear stress, favored anaerobic respiration (Cucullo, Hossain et al.
2013). However, they note that further experiments should be completed to confirm these
results and possible reasons for them.

2.5.4 Cancer Monoculture and Drug Screening Design
Other microfluidic devices aimed at brain cancer do not incorporate endothelial
cells with BBB-like properties as a barrier. Rather they use only cancer cells to grow
tumors under fluid flow to assess the effectiveness of various therapeutics. For example,
in 2016, Fan et al. developed a microfluidic platform for high-throughput screening of the
effectiveness of drugs on a glioblastoma cell line (Fan, Nguyen et al. 2016). They used
poly(ethelene) glycol diacrylate superstructure, to more closely imitate an ECM, and
grew U87 glioblastoma multiforme cells in sphereoid masses in each microwell within
the chip (Fan, Nguyen et al. 2016). They then characterized diffusion of dyes to assess
fluid dynamics, and they treated cells with the conventional chemotherpeutics irinotecan
and pitavastatin individually and in combination. They observed predicted cell death, and
they could determine drug concentrations at each time point. Their matrix, however, did
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absorb some of the drugs, and therefore released them back into the media over time,
adding another unique variable to their device (Fan, Nguyen et al. 2016).

This type of model has the potential to expedite the introduction of personalized
medicine and may be a high-throughput alternative for the screening of novel
compounds, which may be highly effective at treating particular cancers. However,
without the incorporation of BBB-like membranes to assess drug permeability and the
ultimate concentrations which may be available after crossing the BBB, these assays are
largely irrelevant for assessments of novel therapeutics metastatic brain cancers and for
patients who have been diagnosed with them. Therefore, models that incorporate not only
a cancer cell line, but also an endothelium with BBB-like properties, should be pursued.

In addition, though many of these models conceptually improve upon transwell
culture by bypassing the issues of unstirred water layers and unreliable concentration
gradients, and they incorporate other means of BBB recapitulation such as fluid flow,
many of them do not significantly improve barrier tightness in comparison to some
transwell models, which have recently reported maximum TEER values in excess of
1000 Ω cm2 (Patabendige, Skinner et al. 2013). Further, many are so complex, they
require extended amounts of time to produce, seed, and reach the steady states necessary
to perform experiments.
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CHAPTER 3
PERMEABILITY ACROSS THE BLOOD-BRAIN BARRIER AND
BLOOD-TUMOR BARRIER; A NOVEL IN VITRO MODEL ON A
CHIP

3.1 Introduction
The occurrence of brain metastases in breast cancer patients is approximately
10%-16% (Lin, Amiri-Kordestani et al. 2013). Due to improvements in chemotherapy the
overall survival of breast cancer patients has increased. Unfortunately with prolonged
survival the incidence of patients developing symptomatic brain metastases has
increased. One of the leading complications of brain metastases is the inability of drugs
to reach the tumor at dosage levels equivalent to adequately induce cytotoxicity. This is
due, in part, to the presence of a partially intact blood-brain barrier (BBB).

3.1.1 The Blood-Brain Barrier
The BBB is a complex anatomical network, functioning to strictly regulate the
movement of molecules, and ions from the blood to the brain, and back. In addition, the
BBB serves as the conduit to supply the brain with the essential nutrients it needs, while
facilitating the excretion of waste products through efflux (Abbott, Ronnback et al. 2006,
Daneman and Prat 2015). The hallmark of the BBB is the presence of endothelial cells
that are tightly connected by tight junction protein complexes, composed of claudins,
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occludins, and junction adhesion molecules (Serlin, Shelef et al. 2015). In addition to
endothelia, the BBB has a thick basal membrane with pericytes and astrocytic foot
processes in close proximity (Golden and Pardridge 1999, Pardridge 2005). The net effect
of this anatomical structure results in the transendothelial electrical resistance (TEER) of
brain capillaries being ~2,000 ohm*cm2, in comparison to 2-20 ohm*cm2 in peripheral
capillaries (Crone and Christensen 1981, Olesen and Crone 1983). In addition to the
structural components, the BBB his highly enriched in efflux transporters that actively
restrict the entry a large and diverse set of lipophilic solutes from accumulating in the
brain (Loscher and Potschka 2005, Loscher and Potschka 2005, Shen and Zhang 2010,
Adkins, Mittapalli et al. 2013).

3.1.2 The Blood-Tumor Barrier
When metastatic cancer cells invade the central nervous system (CNS) they may
eventually colonize and begin to proliferate into a larger tumor mass. Once the lesion has
grown to a point that it has areas of hypoxia, the tumor will secrete high amounts of
vascular endothelial growth factor in an attempt to develop a new blood supply (Folkman
1971, Ferrara and Davis-Smyth 1997, Neufeld, Cohen et al. 1999, Plate, Scholz et al.
2012). This vasculature (blood-tumor barrier; BTB) is different than the BBB
predominantly because the astrocytes, pericytes and neurons are no longer in close
proximity to the capillary. It is hypothesized that these anatomical changes result in
vasculature that has greater permeability than the BBB (Henson, Cordon-Cardo et al.
1992, Hobbs, Monsky et al. 1998, Liebner, Fischmann et al. 2000, Abbott, Ronnback et
al. 2006, Deo, Theil et al. 2013). The BTB may also have a somewhat different and
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varied expression of efflux transporters depending on the CNS malignancy (Sawada,
Kato et al. 1999, Tews, Nissen et al. 2000, Demeule, Shedid et al. 2001, Lockman,
Mittapalli et al. 2010). Despite the apparent breakdown of the BBB in the presence of a
tumor, the BTB still limits drug movement in to the CNS lesion substantially greater than
in peripheral tumors.

3.1.3 In vitro vs in vivo BBB and BTB Models
Currently, there are no widely validated in vitro models of the BTB. The most
widely used in vitro BBB model, that has been somewhat used to model the BTB, is a
transwell insert system. Briefly, the model consists of upper chamber with endothelial
cells grown on the surface separated from a lower chamber that may or may not have
astrocytes and or cancer cells grown in separated by a porous membrane (Bicker, Alves
et al. 2014, Czupalla, Liebner et al. 2014, Srinivasan, Kolli et al. 2015, Helms, Abbott et
al. 2016). Drug movement is modeled by measuring accumulation in the lower chamber
versus time. The transwell model has limitations. First, there is a lack of flow exerted on
the endothelia resulting in poor cell morphology and a “leakier” barrier compared to in
vivo data (Cucullo, Hossain et al. 2011, Prabhakarpandian, Shen et al. 2013, Czupalla,
Liebner et al. 2014, Deosarkar, Prabhakarpandian et al. 2015, Helms, Abbott et al. 2016).
Second, endothelial cells do not uniformly attach to the outer side of the insert, leaving
gaps between the endothelial cells and the edge of the insert also resulting in increased
permeability (Santaguida, Janigro et al. 2006). Third, an unstirred water later forms on
the surface of the endothelia which results in increased permeability for hydrophilic drugs
and decreased permeability for lipid soluble drugs (Barry and Diamond 1984, Korjamo,
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Heikkinen et al. 2008, Korjamo, Heikkinen et al. 2009, Loftsson 2012, Ghosh, Scott et al.
2014).

Herein we characterize novel in vitro microfluidic models of the BTB and BBB
using a co-culture of endothelial cells and astrocytes along with tumor cells. This model
incorporates flow during culture of the endothelia and has a micro-tubular lumen, which
in other work has substantially reduced limitations seen in transwells (Neuhaus, Lauer et
al. 2006, Cucullo, Marchi et al. 2011, Booth and Kim 2012, Griep, Wolbers et al. 2013,
Herland, van der Meer et al. 2016). This model is unique from other flow based models
in that it allows for a co-culture or triple culture of relevant cells, it is easily duplicated, it
is commercially available and provides a cost-effective solution for running multiple and
parallel assays.

3.2 Materials and Methods
3.2.1 Microfluidic Device
Co-Culture idealized microvascular networks used in this study were obtained
from SynVivo Inc. Huntsville, AL. The device consists of a central compartment
(basolateral) that is comprised of the brain tissue cells (astrocytes, pericytes, neurons) and
the outer compartment (apical) that is comprised of the endothelial cells and provides
perfusion similar to physiological fluid flow conditions. The outer compartments and
central compartment are separated by an interface with a series of 3 µm pores along the
length, replacing the use of membranes in conventional models.
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3.2.2 Chemicals
Sulforhodamine 101 Acid Chloride (Free TRD), Rhodamine-123 (Rho123), Texas
Red 3000 MW Dextran (TRD 3 kDa) and Texas Red 70,000 MW Dextran (TRD 70 kDa)
were purchased from ThermoFisher Scientific (Grand Island, NY). Verapamil was
purchased from Sigma (St. Louis, MO). Cyclosporine A was purchased from Toronto
Research Chemicals Inc. (Toronto, Canada). All other chemicals used were of analytical
grade and were used as supplied.

3.2.3 Cell Culture
Human Umbilical Vein Endothelial Cells (HUVECs) were purchased from Lonza
(Allendale, NJ). CTX-TDR2 rat brain astrocyte cell line was kindly donated by Dr. Jim
Simpkins (West Virginia University, Morgantown, WV). Met-1 murine metastatic breast
cancer cells were a kind gift from Dr. Alexander Borowsky (UC Davis, Sacramento,
CA). All cells were maintained in Endothelial Basal Medium – 2 (EBM-2) supplemented
with the EGM-2 BulletKit from Lonza (Allendale, NJ). Cells were grown in a 37˚C
humidified incubator with 5% CO2 until ~85% confluent.

3.2.4 Cell Culture in Microfluidic Chip
Matrigel (40ug/cm2, EMD Milipore, Billerica MA) was injected into the central
compartment and allowed to sit covered in ice for approximately 1 hour, after which
serum-free media was promptly injected to wash the central compartment. Fibronectin
(200 µg mL-1, EMD Milipore, Billerica MA) was then injected in one of the outer sides
of the device and allowed to incubate at 37˚C overnight. Prior to the seeding of all cells,
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the device was flushed with EBM-2 media. Astrocytes/Met-1 cells were harvested using
TrypLE Select (ThermoFisher, Waltham MA) and re-suspended into a final concentration
of ~1 X 107 mL-1 cells for injection, and were seeded at a flow rate of 10 µL/min in the
central compartment using a Pump 11 Elite Nanomite programmable syringe pump
(Harvard Apparatus, Holliston MA). The inlet port tubing was clamped when cells
reached an intra-central compartment density of ~50% and chip was transferred to a CO2
incubator at 37˚C and allowed to attach for 2 hours. HUVECs were harvested using
TrypLE Select (ThermoFisher, Waltham MA) in the same process as described above,
and re-suspended to a concentration of ~1 X 107 mL-1 and seeded into the outer
compartment previously coated with Fibronectin at a flow rate of 6 µL/min using a Pump
11 Elite Nanomite programmable syringe pump (Harvard Apparatus, Holliston MA).
Inlet port tubing was clamped when HUVECs reached an intra-outer compartment
density of ~90%, then chip was transferred to a CO2 incubator at 37˚C and allowed to
attach for 24 hours. After 6 hours of incubation, medium in central and both outer
compartments was replaced with fresh EBM-2 medium and repeated again at 24 hours.
Astrocyte/Met-1 cells were maintained in the central compartment under static conditions in
EBM-2 medium while EBM-2 medium was prepared in syringes mounted on a
programmable PHD 2000 syringe pump (Harvard Apparatus, Holliston MA), connected
to the chips through ~ 12 inches of sterile Tygon tubing (Harvard Apparatus, Holliston
MA). This medium was flowed at a flow rate of 0.02 µL/min over the seeded HUVECs in
the outer compartment for 4 hours, then increased to 0.05 µL/min after 4 hours, and finally
to 0.1 µL/min after 4 more hours, maintaining a flow of 0.1 µL/min for 24 hours.
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3.2.5 In vitro transport studies
EBM-2 Medium was incubated in a BD Luer-Lok Syringe with either Free TRD
(600 mg/mL), TRD 3 kDa (600 mg/mL), TRD 70 kDa (600 mg/mL), or incubated with
Rho123 (600 mg/mL) in the presence or absence of known P-glycoprotein (p-gp)
inhibitors (verapamil: 50 mM, cyclosporine A: 10 mM) and mounted on a programmable
PHD 2000 syringe pump (Harvard Apparatus, Holliston MA), with syringes connected to
the chips through sterile Tygon tubing (Harvard Apparatus, Holliston MA). Permeability
was measured through the injection of desired tracer into the outer compartment at 0.1
µL/min for a total of 90 minutes while brightfield images (acquired at a 25 ms exposure)
and fluorescent images (acquired at a 200 ms exposure) were acquired every 2 minutes.
Permeability of each tracer was determined using NIS Elements Imaging Software. Using
linear regression (Prism 6.0), the slope of the best-fit line was used to represent the
relative kin, or rate of accumulation, of fluorescence in the central compartment
(comparable to the concentration of drug found in normal brain) divided by the
accumulation of fluorescence in the outer compartment (comparable to the concentration
of drug found in the plasma of the BBB vasculature). Unless otherwise stated, data are
presented as mean ± S.E.M.

3.2.6 Quantification of fluorescent tracers using fluorescent microscopy
Chips were mounted on an automated stage enclosure, maintained at 37˚C with
5% CO2, on a Nikon Eclipse TE2000-E Live Cell Sweptfield Confocal microscope
(Melville, NY). Acquisition of images and fluorescence was achieved through the
utilization of a Photometrics CoolSnap HQ2 Monochrome CCD Camera (Tucson, AZ)
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with a 20x/0.75 Plan Fluor Phase Contrast objective with a total field of 6X8, stitching
images using brightfield with a 10% overlay. Brightfield and fluorescent images were
taken every two minutes for 90 minutes. Excitation and emission of Free Texas Red,
Texas Red 3 kDa and 70 kDa, was obtained using the TRITC epiflourescence filter (peak
fluorophore excitation is 596 nm and emission is 615 nm); excitation filter wheel of
555/25x, emission filter wheel of 605/52m and dichromatic mirror at 89000 sedat quad.
The excitation and emission of Rho123 (+/- cyclosporine A or verapamil) was obtained
using the FITC epiflourescence filter (peak fluorophore excitation is 511 nm and
emission is 534 nm); excitation filter wheel of 490/20x, emission filter wheel of 525/36m
and dichromatic mirror at 89000 sedat quad.

3.2.7 Kinetic analysis
Unidirectional uptake transfer constants (kin) were calculated from the following
relationship to the linear portion of the uptake curve:
(CCC + CPF) / CPF = kin (t) + OC

(Equation 3.1)

Where CCC is the sum intensity of fluorophore in the region of interest in the central
compartment (au) at the end of perfusion, CPF is the sum intensity of fluorophore (au) in
the region of interest within the outer compartment, t is the perfusion time in minutes
from the time the device reached steady state, and OC is the calculated intercept (T = 0
min; "outer compartment volume" (au)). Since the device took 22 minutes to reach steady
state, t=0 minutes is 22 minutes after start of the experiment, but 0 minutes from the start
of steady state. After the determination of a perfusion time where an adequate amount of
fluorescent marker was allowed to pass into brain, while still remaining in the linear
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uptake zone, kin was determined (Takasato, Rapoport et al. 1984, Smith and Takasato
1986).

3.2.8 Statistical Analysis
The slope of the line (kin) was determined with linear regression using best-fit
values. One-way ANOVA analysis and unpaired t test with Welch’s correction, followed
by an F test to compare variances were used for the comparison of the kin values between
unrestricted diffusion, BBB, and BTB among each tracer and with Rho123 in absence
and presence of inhibitors. For all data, errors are reported as standard error of the mean
unless otherwise indicated. Differences were considered statistically significant at the p <
0.05 level. (GraphPad Prism version 6.00 for Mac, GraphPad Software, San Diego, CA,
USA).

3.3 Results
In this study we evaluate BBB and BTB transfer rates of Free TRD, Texas Red 3
kDa, Texas Red 70 kDa, and Rho123 (with and without inhibitors) (Fig 3.1) in a novel
microfluidic BBB and BTB model as validation to previously published literature
(Mittapalli, Manda et al. 2013). Briefly in this model, endothelial cells are seeded in the
outer compartments, while astrocytes (BBB) or brain seeding breast cancer cells (BTB)
are seeded in the central compartment. The porous architecture between the two
compartments allows for cellular crosstalk and biochemical exchanges, while shear stress
from perfusate flow facilitates development of endothelial morphology (Deosarkar,
Prabhakarpandian et al. 2015). Confocal brightfield images show the differences in
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morphology between endothelial cells with and without flow (Fig 3.1B-C). In order to
verify a confluent 360o coating of endothelial cells within the outer compartment, we
used a Nikon A1R Confocal on Eclipse TiE Microscope to acquire a 3D z-stack of the
outer compartment. Utilizing this system, DAPI stained endothelial cells were imaged
from the bottom (Fig 3.2A), through to the top (Fig 3.2B) showing HUVECs wrapping
around the sides of the outer compartment (Fig 3.2C) connecting the HUVECs on the top
to the HUVECs on the bottom, verifying confluent formation of a tubular in vitro
microvasculature.

In initial experiments, we determined unrestricted diffusion rates of different
sized molecules, by perfusing solutes through microfluidic chips without endothelial cells
or astrocytes/cancer cells. To quantify tracer accumulation, regions of interest were
selected to determine sum fluorescence intensity in the outer compartment (ROI 136),
central compartment (ROI 139), and background (ROI 165) over time (3.1D). ROI 165
was taken to ensure data received in the outer and central compartments were significant
when compared to the background sum fluorescence. We observed (Fig. 3.3) that small
tracers (< 1000 Da) had a diffusion rate of 22.8 ± 2.5 X 10-3, n=6, which was not
significantly different compared to tracers of molecular weights between 3-5 kDa (22.1 ±
8.5 X 10-3, n=3) and > 60 kDa (17.5 ± 4.2 X 10-3, n=3).

In our next experiments, we qualitatively imaged Texas Red accumulation from 0
– 90 min in the BBB model (Fig 3.4A-3.4D). Linear accumulation of the dye in the
central chamber of the BBB model is quantitatively shown in Figure 3.4E. We then
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determined kin values for each tracer in both the BBB and BTB model (Equation 3.1).
Free Texas Red kin values (Fig 3.5A) for the BBB (2.5 ± 0.3 X 10-3, n=6) and BTB (13.1
± 1.3 X 10-3, n=4) were significantly different (p < 0.05) between each other. Texas Red
3 kDa values (Fig 3.5B) for the BBB (0.1 ± 0.1 X 10-3, n=3) and BTB (1.8 ± 1.0 X 10-3,
n=3) and Texas Red 70 kDa values (Fig 3.5C) for the BBB (1.1 ± 0.9 X 10-3, n=3) and
BTB (4.5 ± 2.4 X 10-3, n=3) were also significant (p < 0.05) when compared to the
unrestricted diffusion kin but significance was not observed between the BBB and BTB
models of these dyes.

To determine if p-gp inhibitors alter the accumulation of p-gp sensitive
fluorescent dye accumulation into the central compartment we perfused Rho123 in the
absence and presence of p-gp inhibitors cyclosporine A (10 mM), and verapamil (50mM)
(Mittapalli, Manda et al. 2013). We qualitatively observed an increase in dye
accumulation in the central compartment over the course of 90 minutes in both the BBB
(Fig 3.6A) and BTB (Fig 3.6B) models (Fig 3.6C). Quantitatively, we observed a 14fold increase of Rho123 in the central compartment, in the presence of p-gp inhibitor
verapamil (14.7 ± 7.5 X 10-3, n=3), and a significant (p < 0.05) eight fold increase of
Rho123 with cyclosporine A (8.8 ± 1.8 X 10-3, n=3) when compared to control Rho123
(0.6 ± 0.1 X 10-3, n=4) in the BBB model (Fig 3.6D). Similarly in the BTB model, a
three-fold increase was observed in Rhodamine-123 permeability in the presence of p-gp
inhibitor verapamil (10.3 ± 3.1 X 10-3, n=3), and a two-fold increase with cyclosporine A
(7.1 ± 5.2 X 10-3, n=3) when compared to Rho123 control (3.2 ± 2.8 X 10-3, n=3) (Fig
3.6E).
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3.4 Discussion
The results of the studies presented herein suggest that a novel microfluidic chip
in part mimics the in vivo BBB and BTB with regard to passive permeability and efflux
(Adkins, Mohammad et al. 2016). Importantly, this study demonstrates that perfusion
flow through the luminal compartment improves endothelial function. This model also
has potential to be used as in screening assays for drug discovery and development for
central nervous system disease.

Predominant in vitro BBB models have some key similarities. First, there is a
presence of some type of “barrier” cell in a luminal or outer compartment (representing
the vascular lumen). These cells range from primary or immortalized brain endothelial
cells (most commonly rat, mouse, or human), peripheral endothelial (HUVECs), or stemcell derived cells (Stanimirovic, Bani-Yaghoub et al. 2015). These barrier cells typically
express tight junction proteins, which seal the endothelial cells together and produce
higher TEER values (Reese and Karnovsky 1967, Brightman and Reese 1969, Zlokovic
2008). Second the models usually include the presence of a semipermeable basement
membrane separating the outer (lumen) and central (brain side) compartments. Lastly,
cells, typically astrocytes and or pericytes, are seeded in the central compartment in an
effort to mimic the brain microenvironment. The addition of these cells provide cell to
cell communication to the endothelial cells in the outer compartment, resulting in the
formation of tighter barrier and an increase in TEER (Abbott 2002, Coisne, Dehouck et
al. 2005, Garberg, Ball et al. 2005, Pardridge 2005, Pardridge 2007, Abbott, Patabendige

51

et al. 2010, Stanimirovic, Bani-Yaghoub et al. 2015, Helms, Abbott et al. 2016).
Germane to this work, to re-create the BTB, astrocytes and or pericytes are replaced with
tumor cells in the central compartment. In vivo, angiogenesis occurs with the
establishment of tumor tissue, resulting in the presence of fenestrations, gaps between the
endothelial cells, varied expression of efflux transporters, and an increase in permeability
(Schlageter, Molnar et al. 1999, Plate, Scholz et al. 2012).

The use of dyes has been a long-standing method to evaluate the integrity of the
BBB and the breakdown of the BTB. (Ehrlich 1885, Hawkins and Davis 2005, Hawkins
and Egleton 2006, Goldmann 1913). Some of the earliest work using dyes dates back to
the the 19th century, where Paul Ehrlich and Edwin Goldmann intravenously injected
water-soluble dyes and observed that the dyes did not have the ability to freely exchange
between the vascular and brain parenchyma compartment (Ehrlich 1885),(Goldmann
1913). Dyes have also been used as a tool to visualize and qualitatively measure the
disruption at the BBB (Bakay, Ballantine et al. 1956, Schettler and Shealy 1970, da Costa
1972, Nemeroff and Crisley 1975, Lin and Kormano 1977) as well as the BTB
(Mittapalli, Manda et al. 2013, Adkins, Mohammad et al. 2016). Passive permeability
dyes are a simple way to compare rates of diffusion between different models in vivo and
in vitro.

To measure the unrestricted diffusion (the absence of cells) of molecules from the
outer chamber to the center chamber, we observed that the diffusion rates (kin), from the
outer compartment to the central compartment, of all three sized molecules were not
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significantly different from each other. These data are consistent with previous work
showing that if the diameter of each molecule being tested is at least 12x less than the
barrier defects, then diffusion will remain constant for all molecules (Nakagawa,
Groothuis et al. 1987).

An interesting aspect of our observations was the similarity of efflux function that
existed in the microfluidic model compared to the in vivo BBB (Adkins, Mittapalli et al.
2013). Rhodamine-123 is subject to p-gp mediated efflux at both the BBB and the BTB.
When rho123 and an inhibitor of p-gp are administered concurrently, dye accumulates in
brain ~10-12 fold higher than in the absence of efflux inhibition (Mittapalli, Manda et al.
2013). Similarly, in this work when verapamil or cyclosporine A was added to the outer
chamber of the microfluidic device, Rho123 accumulation increased similar to in vivo
reports (Adkins, Mittapalli et al. 2013). Further, p-gp function retains function despite
barrier breakdown in a number of pathologies (Cordon-Cardo, O'Brien et al. 1990,
Adkins, Mittapalli et al. 2013). The data herein agree that the degree of efflux function
for the BTB, though disrupted, is intact and it retains the ability to restrict drug and dye
movement from the vasculature to the brain compartment.

Transwells are a widely used in vitro method to study the BBB. Transwells are
cheap, available in high throughput assays, and easy to use. However, there are
substantial limitations. First, transport kinetics in transwell systems are strongly
influenced by an unstirred water layer that exists on the outer side of the endothelial cells.
The unstirred water layer will decrease the apparent permeability rate of lipid soluble and
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to some extent water-soluble molecules. Second, since the cells are grown in a static
media there is no shear stress (or flow) forced on the endothelial cells, which may
contribute to the low passive permeability measurements which can be as low as ~ 74
ΩŊcm2 (Man, Ubogu et al. 2008), compared to in vivo values of ~ 2000 ΩŊcm2 (Crone and
Olesen 1982)

. While a few other in vitro models and microfluidic devices have a flow

component (Neuhaus, Lauer et al. 2006, Cucullo, Marchi et al. 2011, Booth and Kim
2012, Griep, Wolbers et al. 2013, Herland, van der Meer et al. 2016) this microfluidic
device is the first commercially available blood-tumor barrier using a microfluidic model
utilizing brain-seeking cells with shear stress similar to in vivo (Deosarkar,
Prabhakarpandian et al. 2015) in addition to real-time visualization and quantitation.
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Figure 3.1: Microfluidic chip schematic and methods.

(A) Schematic of the SynVivo BBB Microfluidic Chip: (1) Inlet port where media with
or without tracer is flowed through the outer compartment to change media for
HUVECs. (2) Outer Compartment, containing HUVECs. (3) 3 µm pores, to allow
diffusion of media and tracer between the central and outer compartments. (4) Central
Compartment, containing astrocytes or cancer cells. (5) Outlet port where perfusate from
the outer compartment is collected. (6) Inlet port for central compartment, used to seed
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and change media for the astrocytes/cancer cells in the central compartment. (7) Output
ports where perfusate from the central compartment is collected. (B) Morphology of
astrocytes in the central compartment and HUVECs in the outer compartment without the
addition of flow (C) Morphology of astrocytes in the central compartment and HUVECs
in the outer compartment with the addition of flow. (D) Representation of where the
regions of interest (ROI) measurements are taken for data analysis.
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Figure 3.2: 3-D confocal image of DAPI labeled HUVECs in apical chamber.

3-dimensional confocal images of DAPI labeled HUVECs in the outer compartment
demonstrating a 360o coating of cells. The nuclei of the HUVECs are seen on the bottom
(A) and top (B) and in a side view (C).
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Figure 3.3: Diffusion rates of different sized MW tracers in the same model.

The diffusion rates of free MW tracers < 1000 Da (A), 3 – 5 kDa (B) and > 60 kDa (C) in
an unrestricted, cell free microfluidic chips are shown. Statistical significance was
determined using one-way ANOVA followed by Tukey’s multiple comparison tests, and
student’s t-test; n = 3 – 6 chips. All data represent mean ± SEM.
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Figure 3.4: Representative time-lapse images showing passive diffusion of Free TRD
from the outer to the central compartment.

Intensity of fluorescence increases linearly over time 0 min (A), 30 min (B), 60 min (C),
and 90 min (D). (E) Linear concentration of tracer movement vs time to determine
diffusion constants (Kin).
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Figure 3.5: Linear central compartment accumulation of different tracers in the BBB and
BTB microfluidic chip models.

Linear central compartment accumulation of Free TRD (A), TRD 3kDa (B), and TRD 70
kDa (C) in BBB and BTB SynVivo chip models. Images show rate of each tracer within
each model. Statistical significance was determined using one-way ANOVA followed by
Tukey’s multiple comparison tests, and student’s t-test; * p < 0.05 significance between
tracer and unrestricted diffusion kin, n = 3-6; + p < 0.05 significance between BBB and
BTB models, n=3-6. All data represent mean ± SEM.
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Figure 3.6: Rhodamine-123 permeability with and without inhibitors in BBB and BTB
models.

Representative brightfield image of Rho123 dye accumulation in the central compartment
after 90 minutes of perfusion in the BBB model without an inhibitor (A) and with an
inhibitor (B). Rate of fluorescent dye accumulation of Rho123 into central compartment
after 90 min of dye perfusion in BBB, and BTB chips (C). Rate of fluorescent dye
accumulation in BBB (D) and BTB (E) chips perfused with Rho123 +/- p-gp inhibitors
(cyclosporine A or verapamil). Statistical significance was determined using one-way
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ANOVA followed by Tukey’s multiple comparison tests, and student’s t-test; * p < 0.05
significance between tracer and unrestricted diffusion kin, n=3-4; + p < 0.05 significance
between BBB/BTB models and the addition of inhibitor, n=3-6. All data represent mean
± SEM.
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CHAPTER 4
TRASTUZUMAB EFFICACY IN AN IN VIVO AND IN VITRO
MODEL OF BRAIN METASTASES OF BREAST CANCER

4.1 Introduction
Brain metastases are a fatal neurological complication of breast cancer which
have historically been a major cause of morbidity. Women with symptomatic central
nervous system (CNS) metastases have a median survival of approximately 4 months
(Colzani, Liljegren et al. 2011). Furthermore, less than 2% of women survive two years
post-diagnosis (Zimm, Wampler et al. 1981). The risk of developing brain metastasis has
been reported to range from 10 to 16 % among advanced-stage breast cancer patients,
making it the second most common cause of metastatic brain tumor after lung cancer
(10–25%) (Palmieri, Smith et al. 2006, Park, Park et al. 2009, Steeg, Camphausen et al.
2011, Lin 2013, Yeh, Yu et al. 2015).

Among the many associated risk factors in the development of brain metastases
from breast cancer, hormone receptor status is one of the most important (SanchezMunoz, Plata-Fernandez et al. 2013). Within the HER2-positive subset, hormone receptor
status appears to further define the risk of CNS relapse. Patients with hormone receptornegative/HER2-positive tumors experience increased risk of the CNS as site of first
relapse as compared to patients with hormone receptor-positive/HER2-positive tumors
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(Bendell, Domchek et al. 2003, Palmieri, Bronder et al. 2007, Leyland-Jones 2009, VazLuis, Ottesen et al. 2012). Up to 37% of patients with HER2-positive breast cancer
relapse due to intracranial metastases, despite control of the peripheral tumors (Clayton,
Danson et al. 2004, Witzel, Oliveira-Ferrer et al. 2016). Palmieri et al. demonstrated that
Her-2 overexpression increases the outgrowth of metastatic tumors cells in the brain in
breast carcinoma cell lines (Palmieri, Bronder et al. 2007). A limiting factor in the
treatment of brain metastases is the inability of chemotherapy to reach the desired tumor
location. This is due, in large part, to the presence of a strictly controlled and regulated
complex network known as the blood-brain barrier (BBB).

The BBB is a physical and functional barrier limiting passive diffusion of
extrinsic agents into brain (Ballabh, Braun et al. 2004, Dauchy, Miller et al. 2009,
Abbott, Patabendige et al. 2010, Cook and Freedman 2011). The BBB is mainly formed
of endothelial cells, in addition to pericytes, astrocytes and neuronal cells that play an
important role in the function of the BBB (Rip, Schenk et al. 2009). BBB endothelial
cells have specific characteristics, such as the expression of tight junctions, which prevent
passive paracellular transport of most water soluble compounds and many lipid soluble
compounds with the exception of small gaseous compounds like carbon dioxide and
molecular water (Ballabh, Braun et al. 2004, Hawkins and Davis 2005, Rip, Schenk et al.
2009, Abbott, Patabendige et al. 2010, Abbott and Friedman 2012, van Tellingen, YetkinArik et al. 2015).
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The function and organization of the BBB may be altered under pathological
conditions. In the case of tumors, the BBB’s structure and integrity are altered forming
the “Blood-Tumor Barrier” (BTB) (van Tellingen, Yetkin-Arik et al. 2015). The BTB
differs from the BBB in its decreased tight junction expression (Liebner, Fischmann et al.
2000), a disruption of the basement membrane (Deo, Theil et al. 2013) and an increase in
permeability (Tate and Aghi 2009, Puhalla, Elmquist et al. 2015). However, radiologic
data have shown that not all brain metastases display elevated BTB permeability (Lin,
Bellon et al. 2004). The changes in BTB vascular permeability are typically
heterogeneous throughout the tumor site (Lockman, Mittapalli et al. 2010, Villanueva
2013). It has been observed that brain metastases from HER2+ breast cancers infiltrate
brain parenchyma without disrupting the BBB, unlike brain metastases from triple
negative or basal-type breast cancers, which often disrupt the BBB (Yonemori, Tsuta et
al. 2010, Vaz-Luis, Ottesen et al. 2012, Witzel, Oliveira-Ferrer et al. 2016). Targeted
therapies have revolutionized cancer treatment, potentially offering an improved
therapeutic ratio (Boskovitz, Wikstrand et al. 2004), such as small molecule inhibitors
(Hoelder, Clarke et al.) and monoclonal antibodies (Boskovitz, Wikstrand et al. 2004).
However, the ability of these drugs and antibodies to permeate the brain and brain
metastases is highly debated.

In this work, we have tested the permeability of I125-trastuzumab in an in vivo, and
fluorescent trastuzumab-Rho123 (t-Rho123) in a novel in vitro model of brain metastases
of breast cancer. This is one of the first studies to measure antibody movement across the
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blood-brain and blood-tumor barriers, demonstrating accumulation of trastuzumab in
brain metastases of breast cancer with confirmatory experiments in vitro.

4.2 Materials and Methods
4.2.1 In Vitro Studies:
4.2.1.1 Chemicals and Reagents
Texas Red 70,000 MW Dextran (TRD 70 kDa) was purchased from Molecular
Probes (Invitrogen, Carlsbad, CA). Trastuzumab (Herceptin®, Genentech/ Roche) was
buffer-exchanged into 50 mM potassium phosphate buffer and 150 mM sodium chloride
adjusted to pH of 6.7. Trastuzumab was fluorescently linked to Rhodamine-123 (Innova
Biosciences, Babraham, England). All other chemicals are of analytical grade and were
purchased from Sigma-Aldrich (St. Louis, MO).

4.2.1.2 Cell culture for in vitro studies
Human Umbilical Vein Endothelial Cells (HUVECs) were were purchased from
Lonza (Allendale, NJ). CTX-TDR2 rat brain astrocyte cell line were harvested,
expanded, and generously provided by the laboratory of Dr. Jim Simpkins (West Virginia
University, Morgantown, WV). Both HUVEC and astrocyte line were cultured and
maintained in Endothelial Basal Medium – 2 (EBM-2) with the supplementation of
EGM-2 BulletKits from Lonza (Allendale, NJ). The laboratory or Dr. Patricia Steeg, of
the National Cancer Institute, generously provided a JIMT-1 brain metastases of breast
cancer cell line, a line which naturally overexpresses HER2+. These cells were cultured
and maintained in DMEM supplemented with 10% Fetal bovine serum and 1% penstrep.
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All cell lines for in vitro studies were grown within a 37˚C humidified incubator with 5%
CO2 until ~85-90% confluent.

4.2.1.3 Cell Culture in Microfluidic Chip
The co-culture idealized microvascular microfluidic chips used in this study were
obtained from SynVivo Inc (Huntsville, AL). These microfluidic chips were prepared,
then cultured with cells and maintained as previously described (SynVivo, Chapter 3)
(Prabhakarpandian, Shen et al. 2013).

4.2.1.4 Transport studies and quantification using fluorescent microscopy
For each device, a BD Leur-lok syringe connected to Tygon tubing was filled with EBM2 media containing fluorescent tastuzumab and mounted on a programmable Harvard
PHD 2000 syringe pump (Harvard Apparatus, Holliston, MA). Chips were maintained at
37˚C with 5% CO2 and mounted in an automated stage enclosure on a Nikon Eclipse
TE2000-E Live Cell Sweptfield Confocal microscope (Melville, NY). Permeability was
measured through the perfusion of fluorescently labeled trastuzumab through the outer
chamber at 0.1µL/min. Brightfield (25 ms exposure) and TRITC (200 ms exposure)
images were acquired every two minutes for 90 minutes with a Photometrics CoolSnap
HQ2 Monochrome CCD Camera (Tucson, AZ) with a 20x/0.75 Plan Fluor Phase
Contrast objective with a total field of 6X8, stitching images using brightfield with a 10%
overlay. Following acquisition, NIS Elements Imaging Software was used to determine
Regions of Interest (ROI) and data exported to Prism 6.0. A line of best fit was
determined using linear regression (Prism 6.0), and the slope represents the relative rate
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of accumulation of fluorescence (kin) in the central chamber (representing drug
concentration found in normal brain) divided by the amount of fluorescence in the outer
chamber (representing drug concentration found in the BBB/BTB vasculature). Unless
otherwise noted, data are presented as mean ± S.E.M.

4.2.1.5 Kinetic analysis
Unidirectional uptake transfer constants (kin) were calculated using the following
equation:
(CCC + CPF) / CPF = kin (t) + OC
(Equation 4.1)
Where CCC is the sum intensity of fluorophore in the region of interest in the central
compartment (au) at the end of perfusion, CPF is the sum intensity of fluorophore (au) in
the region of interest within the outer compartment, t is the perfusion time in minutes
from the time the device reached steady state, and OC is the calculated intercept (T = 0
min; "outer compartment volume" (au)). Since the device took 22 minutes to reach steady
state, t=0 minutes is 22 minutes after start of the experiment, but 0 minutes from the start
of steady state. After the determination of a perfusion time where an adequate amount of
fluorescent marker was allowed to pass into brain, while still remaining in the linear
uptake zone, kin was determined (Takasato, Rapoport et al. 1984, Smith and Takasato
1986).

4.2.1.6 Statistical Analysis
Using linear regression with best-fit values, the slope of the line (kin) was determined.
One-way ANOVA analysis, unpaired student t test’s with Welch’s correction, and an F
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test to compare variances were used for the comparison of kin values between the
unrestricted diffusions, BBB, and BTB models,. For all data, errors are reported as
standard error of the mean unless otherwise indicated. Differences were considered
statistically significant at p < 0.05. (GraphPad Prism version 6.00 for Mac, GraphPad
Software, San Diego, CA, USA).

4.2.2 In Vivo Studies:
4.2.2.1 Chemicals and reagents
Texas red conjugated 625 MW dextran (TRD 625 Da) was purchased from Molecular
Probes (Invitrogen, Carlsbad, CA). Trastuzumab (Roche) was buffer-exchanged into 50
mM potassium phosphate buffer and 150 mM sodium chloride adjusted to pH of 6.7.
Trastuzumab was radiolabeled with 125I. All other chemicals are of analytical grade and
were purchased from Sigma-Aldrich (St. Louis, MO).

4.2.2.2 Cell culture
Human MDA-MB-231-HER2+ metastatic breast cancer cells expressing enhanced green
fluorescent protein (eGFP) and the luciferase construct, were cultured in DMEM
supplemented with 10% fetal bovine serum and zeocin (300 µg/ml). Cells were harvested
at 80% confluency for intracardiac injection. All cell lines were generously provided by
the laboratory of Dr. Patricia Steeg at the National Cancer Institute.
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4.2.2.3 Experimental brain metastases model
Homozygous Female NuNu (n=20) mice were obtained from Charles River Laboratories
(Kingston, NY) and used for all experiments in this study. All animals were 6–8 weeks of
age at the initiation of the metastases models and were housed in a barrier facility. All
studies were approved by the Animal Care and Use Committee at Texas Tech University
Health Sciences Center and conducted in accordance with the 1996 NIH Guide for the
Care and Use of Laboratory Animals. Mice were anesthetized with 2% isoflurane and
inoculated with 175,000 breast cancer cells in the left cardiac ventricle with the aid of a
stereotaxic device (Stoelting, Wood Dale, IL). The inoculum circulates in the peripheral
vasculature, arrests in brain capillaries, extravasates across the blood-brain barrier (BBB),
and mice develop metastatic lesions predominantly in the brain (Lockman, Mittapalli et
al. 2010). After intracardiac injection, mice were placed in a warmed (37 °C) sterile cage
and their vitals monitored until fully recovered. Metastases were allowed to develop and
visualized with bioluminescent imaging, until neurologic symptoms appeared (~32 days),
and animals were anesthetized with ketamine/xylazine (100 and 8 mg/kg respectively)
prior to injection with 125I-trastuzumab via IV bolus dose (femoral vein). 125I-trastuzumab
was allowed to circulate for 24h. TRD 625 Da was injected intravenously (femoral vein).
10 minutes’ post-injection, blood samples were obtained and mice were euthanized
decapitated.

4.2.2.4 Harvesting of the brain and other tissues and organs
Animals were euthanized, brain tissue rapidly removed (less than 60 seconds), and placed
in isopentane (-65°C). Brains were sliced (20 µm) using a cryostat (Leica Microsystems,
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Wetzler, Germany), and sections were mounted on charged gold plated glass slides, air
dried, and stored at -80 °C. In addition to the brain, blood and samples from other organs
(heart, lungs, liver, spleen, kidney) were collected, washed, and weighed for comparative
analysis. Radioactivity was measured immediately following collection (Tri-CARB
2900TR, Perkin Elmer) and expressed as cpm/mg then converted to nCi/g. Distribution
ratios are expressed as the amount of radioactivity in the tissue/blood normalized by
weight.

4.2.2.5 Quantitative autoradiography (QAR)
Slides were placed in QAR cassettes (FujiFilm Life Sciences, Stamford, CT) along
with 125I autoradiographic standards (Amersham Biosciences). A phosphor screen
(FujiFilm Life Sciences, 20 × 40 super-resolution) was placed on the slides and standards
and allowed to develop for up to 14 days. QAR phosphor screens were developed in a
high-resolution phosphor-imager (FUJI FLA-7000, FujiFilm Life Sciences) and
converted to digital images. Digital QAR images were calibrated to 125I standards and
analyzed using MCID Analysis software (InterFocus Imaging LTD, Linton, Cambridge,
England). Metastases permeability fold-changes were calculated based on 125I signal
intensity within confirmed metastases locations (determined by eGFP fluorescence image
overlays) relative to 125-I signal intensity in normal brain.
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4.2.2.6 Fluorescence measurement
Texas red fluorescence was imaged using a DsRed sputter filter (excitation/band λ
545/25 nm, emission/band λ 605/70 nm and dichromatic mirror at λ 565 nm) (Chroma
Technologies, Bellows Falls, VT) and eGFP (expressed in MDA-MB-231BR-HER2+)
using an ET-GFP sputter filter (excitation/band λ 470/40 nm, emission/band λ 525/50 nm
and dichromatic mirror at λ 495 nm) (Chroma Technologies, Bellows Falls, VT).
Fluorescence image capture and analysis software (SlideBook 5.0; Intelligent Imaging
Innovations Inc., Denver, CO) was used to obtain and quantify fluorescence images.
Texas red permeability fold-changes were determined by Texas Red Sum intensity (SI)
per unit area of metastases relative to the SI per area of contralateral normal brain
regions. If metastases occurred in contralateral regions, adjacent slices containing
unaffected tissues of the same brain structure were used as comparative normal brain
regions.

4.2.2.7 Unidirectional uptake transfer constants (Kin)
Kin values were then calculated from brain distribution volume versus time as
previously described (Lockman, Mittapalli et al. 2010).

4.2.2.8 Bioluminescent imaging
Mice were injected with D-luciferin potassium salt (150mg/kg; PerkinElmer,
Waltham, MA) dissolved in sterile 1X PBS via intraperitoneal (IP) injection and then
anesthetized with 2% isoflurane. Fifteen minutes after IP injection of D-luciferin,
darkfield images of mice were acquired with an IVIS Lumineer XV (PerkinElmer) to
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detect bioluminescence. Animals were imaged 1, 3, 6, 9, 12, 24, 48, 72, 96, 120, 144, and
168 hours post intracardiac injection to ensure successful tumor injection and growth.

4.2.2.9 Data analysis
Statistical significance was determined by Student’s t-test and one-way ANOVA
followed by Bonferroni’s multiple comparison’s tests. All differences were considered
statistically significant at p< 0.05. Data is reported as Mean ± Standard Deviation (SD)
unless otherwise noted (GraphPad Prism 7.0, San Diego, CA). Results associated with
drug concentration in tumor and brain distant to tumor (BDT) are Mean values of
combined readings from all tumor and BDT areas in the study group without separation
by individual animal data. In the case of Kin analysis (Lockman, Mittapalli et al. 2010),
values obtained at individual time points were also pooled together.

4.3 Results
To visualize in vitro movement of t-Rho123, microfluidic BBB and BTB chips
(Fig. 4.1A) were established and utilized as previously published (Prabhakarpandian,
Shen et al. 2013). The distribution of t-Rho123 in BBB and BTB models was analyzed.
Using Equation 4.1, we observed a linear increase of fluorescent trastuzumab uptake in
both the BBB (0.27 ± 0.33 X 104) (Fig. 4.1C) and BTB (1.29 ± 0.93 X 104) (Fig. 4.1D)
models significantly greater than 0 (p < 0.05). The rate of movement of fluorescent
trastuzumab was quantified through the addition of a region of interest in the outer
chamber (comparative to concentration of drug in plasma, CPF) and a region of interest in
the central chamber (comparative to concentration of drug in brain, CCC), then divided by
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the sum intensity of tracer in the outer chamber (CCC + CPF / CPF) and plotted over time.
The slope of this line, Kin (µL/min/µm2), was plotted and graphed (Fig. 4.1B) as the
mean ± S.E.M. for the BBB (0.18 ± 0.05, n=3) and BTB (2.12 ± 1.36, n=3) models. Both
the Kin for the BBB models as well as the heterogeneity of the Kin values in the BTB
models were comparable to in vivo. The BBB (p<0.0033) and BTB (p<0.0005) models
were significantly different in comparison to the unrestricted diffusion Kin of this model,
as previously described (SynVivo, Chapter 3).

Organ distribution of trastuzumab after intracardiac (left ventricle) injection of 20
Nu/Nu mice with the HER2+ breast cancer cell line was determined. After the mice were
developed metastases (~32 days), radio-labeled 125I-trastuzumab was injected and
allowed to circulate, followed by the administration of TRD 10 minutes prior to
decapitation. Quantitative autoradiography (QAR) was used to measure the brain tissue
distribution of 125I-trastuzumab. Figure 4.2A represents organ distribution of 125Itrastuzumab, variability in different body organs is observed. 125I-trastuzumab was found
in significant quantities in spleen (5.04%, SD= 3.91), lungs (4.45%, SD= 2.08), liver
(3.54%, SD= 2.26), kidney (3.12 %, SD= 2.06), and heart (3.08%, SD= 1.78) compared
to normal brain (0.30%, SD= 0.22) and tumor brain tissues (0.46%, SD= 0.46). The
accumulation of 125I-trastuzumab in tumor brain was 1.5 fold higher than normal brain
tissue (p<0.0001) (Fig. 4.2B).

Heterogeneous and limited distribution of 125I-trastuzumab in a preclinical brain
metastases of breast cancer model is shown in Figure 4.3A- 4.3C. Metastases were
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categorized into four groups based upon the magnitude of permeability change compared
to normal brain; where low, intermediate, medium and high corresponds to < mean brain
+ 3xSD; > mean brain + 3xSD but < 2 fold; 2-4 fold; high is > 4 fold, respectively. The
mean and standard deviation of the four groups were, 1.30 and 0.34 for low permeability,
1.88 and 0.07 for intermediate permeability, 2.79 and 0.61 for medium permeability, and
7.40 and 4.66 for high permeability (Fig. 4.3D).

Fold increase in 125I-trastuzumab (over normal brain) was plotted versus
metastasis size (mm2) in individual 231-Br-Her2 brain metastases (Fig. 4.3E). No clear
correlation was found between the size of brain metastases and the amount of 125Itrastuzumab localized (Fig. 4.3E). Kin values were determined separately for normal and
tumor areas of the brain (Fig. 4.3F). Mean Kin for normal brain tissue was 1.457x107
mL/sec/g (SD= 0.55) while mean Kin in the case of tumor brain was 3.80 mL/sec/g (SD=
2.17). There was minimal correlation between fold increase of 125I-trastuzumab and the
lesion size.

4.4 Discussion
Treatment of brain metastases of breast cancer conventionally consists of surgery,
whole brain radiation, stereotactic radiosurgery, chemotherapy, and/or biological
therapies (Rostami, Mittal et al. 2016). Various chemotherapeutic agents have shown
only a modest effect on survival due to their limited ability to cross the blood brain
barrier (BBB) (Rostami, Mittal et al. 2016). In a preclinical study using two different
models of brain metastases of breast cancer, most metastases exhibited some increased
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BTB permeability in comparison to normal brain. However, BTB permeability remained
poorly correlated with lesion size, and only approximately 10% of lesions with the
highest permeability exhibited cytotoxic responses to paclitaxel or doxorubicin
(Lockman, Mittapalli et al. 2010). In low-grade gliomas, the BTB resembles a normal
functioning BBB, while in high-grade gliomas, BTB is disrupted “leaky”, as it is
characterized by major alterations of the normal vascular function, shown through
contrast-enhanced MRI by Dhermain et al. (Dhermain, Hau et al. , van Tellingen, YetkinArik et al. 2015). However, the magnitude of this local disruption is unlikely to be
sufficient to allow drug penetration in meaningful quantities, and is thus considered a
major obstacle for drug delivery to the brain (Tzeng and Green 2013).

Trastuzumab (Herceptin®, Genentech/ Roche), is a widely used humanized
monoclonal antibody, for the treatment of HER2+ breast cancer due to its ability to
recognize and bind to the extracellular juxtamembrane domain of HER2. Through this
binding, trastuzumab is able to inhibit the proliferation, therefore survival, of HER2dependent tumors (Park, Park et al. 2009). The ability of trastuzumab to significantly
cross the BBB is unclear (Kute, Lack et al. 2004). Şendur et al (Sendur, Uncu et al. 2014)
reported a case study using a combination of lapatinib and capecitabine followed by
trastuzumab in HER2-positive brain metastatic breast cancer. No progression of cranial
metastases was found post-treatment. In another case series by Mutlu et al (Mutlu and
Buyukcelik 2015), one in three patients with HER-2 positive breast cancer brain
metastasis maintained the brain metastases post-treatment with a combination of weekly
trastuzumab plus vinorelbine. In an in vivo study by Kodack et al, it was observed that
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through the use of a combination of a HER2 inhibitor with an anti–VEGF receptor-2
antibody, trastuzumab, and lapatinib, tumor growth was significantly slowed in the brain,
resulting in increased survival in a mouse model of HER2-amplified breast cancer brain
metastasis using an orthotopic xenograft of BT474 cells (Kodack, Chung et al. 2012).

In patients without brain metastases, the ratio of trastuzumab in plasma to
trastuzumab in cerebrospinal fluid is > 300:1 (Pestalozzi and Brignoli 2000). Lampson
found that monoclonal antibodies were able to reach brain metastases in only 2 models
(Lampson 2011): blood-borne tumor from outside the brain, and dormant tumor that
grows enough to rupture the BBB, and thus allow mABs to infiltrate. In addition to
physical barriers, several functional barriers contribute to the restrictive nature of BBB,
which represents a major obstacle to effective drug delivery into the CNS (Deeken and
Loscher 2007). A group of efflux transporters (such as P-glycoprotein, breast cancer
resistance protein, and multidrug resistance-associated proteins) are expressed on the
brain endothelia, and collectively cause rapid efflux of a large group of lipophilic drugs
from the CNS (Loscher and Potschka 2005). The use of novel P-glycoprotein inhibitors
in enhancing BBB permeation, drug uptake, and retention has been an area of recent
investigation (Andersson, Hansen et al. 2013, Andersson, Badisco et al. 2014, Bauer,
Karch et al. 2015).

This model has been previously used to observe small molecule movement and Pglycoprotein efflux (SynVivo, Chapter 3). Through the utilization of this device, we
observed a relatively similar fold increase of trastuzumab in vivo as compared to the in
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vitro observation in the microfluidic device when comparing fold increases from the
blood-brain barrier to the blood-tumor barrier. The prediction and evaluation of the
ability of various therapeutic and diagnostic moieties to cross the BBB and BTB, as well
as brain uptake kinetics are critical to progress efficient brain metastases therapy and
diagnosis from basic to translational research. Such knowledge is urgently needed for the
early detection and management of high-risk brain metastases in patients. This study
demonstrates that, though in minute quantities, trastuzumab does in fact cross the bloodbrain and blood-tumor barriers. The heterogeneity of antibody dispersion observed within
the in vivo tumors mimics that seen in the in vitro tumor model. Expanding on these data,
future work should include the use of additional antibodies used to treat brain metastases
of breast cancer, as well as the addition of different small molecule inhibitors.
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Figure 4.1: Mechanism of trastuzumab movement.

Linear central compartment accumulation of 125I-trastuzumab in in vitro BBB and BTB
microfluidic chip models. Representative image of model with TRITC labeled 125Itrastuzumab flowing over HUVEC cells in the outer compartment and either astrocytes or
JIMT-1 cancer cells in the central compartment (1A). Rate of 125I-trastuzumab movement
in each model plotted against the unrestricted diffusion kin; ** p<0.0033 significance
between BBB model and unrestricted diffusion kin, n=3; *** p<0.0005 significance
between BTB model and unrestricted diffusion kin, n=3. All data represent mean ±
S.E.M. Each model is significantly different than 0 (p < 0.05) (1B). Representative
graphs of the rate of accumulation of 125I in the BBB (1C) and BTB (1D) microfluidic
devices.
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high is >4 fold, respectively (Values represent mean ± SD, n=251 metastases)
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(3E). The correlation was minimal with
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I-trastuzumab fold increase versus

lesion size. K in values for normal and tumor areas of the brain (3F).
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS

5.1 Conclusions
This dissertation set out to study the distribution and efficacy of
chemotherapeutics in a novel, microfluidic, in vitro preclinical model of brain metastases
of breast cancer. Chapter 2 is an in depth review of the current static and microfluidic in
vitro models most commonly available to researchers. This review shows that a new,
commercially available model that mimics in vivo is drastically needed for the
advancement of blood-brain barrier (BBB) and blood-tumor barrier (BTB) research. This
review article further set out to evaluate the performance of cell-based in vitro systems of
the BBB. It was found to be very difficult to evaluate the performance of the plethora of
different models used because of the lack of coherence in the research field. The authors
therefore call for a more standardized method to evaluate the performance of the different
in vitro systems developed as an effort to jointly bring the research field forward. In
pursuit of a widely-applicable, cost-effective, and accurate in vitro model of the BBB and
BTB at the brain, all of the discussed microfluidic evices must be taken into
consideration.

In chapter 3, we set out to validate a novel and dynamic microfluidic in vitro BBB
model. Through various permeability studies, we found that the permeability of large
molecule dextrans, as well as small molecule dextrans, and Rhodamine-123 (with and
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without inhibitors) were characteristic and relatable to what is seen in vivo. The added
shear stress exerted on the endothelial cells from the addition of flow eliminated the
unstirred water layer and allowed for different tracers to be added and real-time followed
from outer (apical) to central (basolateral) compartment. P-glycoprotein (p-gp) was also
shown to be functional and intact in both BBB and BTB models, and relatable to current
in vivo data. We found that this novel microfluidic in vitro device successfully mimicked
the in vivo barrier in regard to shear stress, permeability, and efflux. Based on these
characteristics, this microfluidic chip shows potential for use in BBB and BTB research.

When it comes to drug and antibody distribution across the BBB and BTB, the
literature is conflicting and this topic continues to be highly debated. Despite the partial
breakdown of the barrier, the BTB still exhibits efflux transporters (and other BBB
properties) to a highly functioning degree, causing difficulties in the delivery of most
drugs. The aim of Chapter 4 was to test the distribution of trastuzumab in both an in vivo
and in vitro model. This chapter demonstrates that, though in minute quantities,
trastuzumab does in fact cross the blood-brain and blood-tumor barriers. The
heterogeneity of the antibody dispersion observed within the in vitro tumors mimics that
seen in the in vivo tumor model. Expanding on these data, future work should include the
use of additional antibodies used to treat brain metastases of breast cancer, as well as the
addition of different small molecule inhibitors.
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5.2 Future Directions
Throughout this dissertation, specifically during the validation of the microfluidic
chip in chapter 3, multiple obstacles occurred throughout the experiments, leading to
months of troubleshooting and the redesigning of projects. However, due to these
obstacles, we have worked diligently with the CFD Research Corporation to develop,
bioengineer, and restructure multiple variations to the current microfluidic chip. The
proposed bioengineering modifications (Fig. 5.1) will allow for a greater diversification
in the types of experiments that will be able to be run through this chip, as well as helping
validate this in vitro model even further.

5.2.1 Engineering Modifications
The biggest limitation with the current microfluidic chip is the inability to
measure transendothelial electrical resistance (TEER) values across the different barriers.
TEER is a quantitative technique used to measure integrity of the BBB and BTB, and
allows for comparison between models. In vivo, the TEER of brain capillaries is ~2,000
ohm*cm2 (Crone and Christensen 1981, Olesen and Crone 1983), where as the TEER of
the standard in vitro static BBB transwell is 25 Ω cm2 (Booth and Kim 2012). We have
worked thoroughly with CFD Research Corporation to redesign their microfluidic device
to adequately measure real time TEER in a way as to not disrupt the cell culture
conditions. In order to measure TEER, three different components are required; 1) ports
for insertion of electrodes, 2) development of electrodes and 3) portable and costeffective instruments for real-time monitoring. Figure 5.2 shows a conceptual schematic
of the design for TEER measurement with the circles indicating location for electrodes
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insertion. Every in vitro model has the ability for a TEER value to be measured, allowing
for the comparison of the tightness of that model’s barrier to in vivo so with this
bioengineering modification, the ability of this microfluidic chip to create an substantial
and significant BBB will be able to be measured and directly compared to all other in
vitro, and in vivo, models.

Initially, when the projects for Chapter 3 began, we incorporated the use of five
different compounds, including small and large molecules as well as a couple
radiolabeled chemotherapeutics to add to the validation of this model in regards to drug
movement across the BBB and BTB. When we began to run the experiments, a limitation
that we observed was the very small size of the recovery ports. This limited the recovery
of radiolabeled compounds and consequently we could not complete analysis. In the
current design of the chip, the entire apical chamber, from the input to the recovery port
only holds 0.806µl, with the central chamber holding only 1.795 µl (Fig. 5.3). Because of
this limitation, we began to formulate the basis for a modified chip with larger port and
chamber volumes, in order to run radioactive experiments. The proposed CAD layout of
the optimized design and parameters of the modified chip is shown in Figure 5.4. The
modifications include the changing of the circular central chamber to an elongated
chamber design, and lengthening the overall device, allowing it to span the entire
microscope glass slide. With these modifications, perfusate samples will to 10-20µl of
sample for perfusate analysis, allowing for the integration of a vast amount of varying
compounds and drugs.
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The last engineering modification to this device is to modify the device in
order to isolate metastatic cells with varying metastatic potential. The mechanism of
tumor cell extravasation is unknown and has not been successfully studied in vitro. The
extravasation of tumor cells has been previously shown with this microfluidic device (Fig
5.5), though the mechanism has not been elucidated, due in part to the inability to retrieve
individual, or selective, tumor cells from the device. The first step for future modification
is to alter the central chamber to 1) allow for quantification of cells based upon metastatic
potential and 2) be able to collect cells with varying metastatic potential for next
generation sequencing. One of the most exciting aspects of this modification is that the
genomic driving forces of BBB cancer cell extravasation would be understood through
the experiments using next generation sequencing of cells that can cross the BBB
endothelia. In order to isolate the cells for single cell populations, the system will be
redesigned as shown in Figure 5.6. The output of the central chambers will be distributed
into multiple channels to separate cells with different metastatic potential. Each of the
channels will be injected into a sample tube for isolation and analysis. Figure 5.6 also
shows examples of fluidic isolation for separation based on the outlets. This modification
has the potential to lead to significant insights and potentially druggable targets for
cancer cells invading brain, something that has not yet been studied.

5.2.2 Biological Modifications
Throughout my project I utilized Human Umbilical Vein Endothelial Cells
(HUVECs) as my endothelial cells of choice due to their ability to be used until a high
cell culture passage, and the relative ease in the culturing ability. However, it was
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brought to our attention that HUVECs may not be the best model to use in vitro to mimic
the in vivo BBB. So to address this, we have postulated modifications in the device to
improve cell culture conditions. Within these modifications, it might be of interest to
utilize Dr. Eric Shusta’s model. Shusta utilizes human pluripotent stem cells that are
simultaneously co-differentiated to both neural and endothelial lineages. By doing this,
these cells produce an embryonic brain-like in vitro micro-environment that generates
human pluripotent stem cells-brain microvascular endothelia cells. These cells would be a
great cell to use for recreating the blood-brain or blood-tumor barriers because these cells
have been shown to possess BBB endothelial characteristics such as well-developed tight
junctions, high TEER, low passive permeability, and active and polarized efflux
transporters (Perriere, Yousif et al. 2007, Lippmann, Azarin et al. 2012), all
characteristics that are important in the in vivo BBB.

In addition to modifying the endothelial cells, other biological modifications can
be utilized to further verify the model through the use of different brain metastases cells
(human pluripotent stem cells, patient derived xenografts (PDXs), JimtBr cells and
MDA-MB-231Br cells) to create various different brain microenvironments, as well as
the study of the permeability of each cell line in vitro and to be able to compare to the
relative in vivo data. As the incidence of brain metastases of breast cancer continues to
increase, the need for affordable, accessible, and accurate portrayals of the in vivo BBB
in the form of in vitro models also increases. It is our hope that through these
modifications, these microfluidic chips will become a widely accepted in vitro model,
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meeting and exceeding all of the aforementioned desires of a clinically relevant in vitro
model.
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Creation of a Microfluidic Flow-Based BTB model

PDX cells
or
Brain seeking
Breast Cancer
Cells

Engineering Modifications
• Real time TEER measures
• Increased recovery ports
• Isolate metastatic cells with
varying metastatic potential
Biological Modifications
• Brain Metastases Cells
• PDX cell lines
• JimtBr
• MDA-MB-231Br
• Endothelial Cells
• HUVEC
• Human pluripotent stem cells

Figure 5.1: Microfluidic BTB device overall modifications

Inlet ports where perfusion flow enters outer chamber (A) and central chamber (C).
Apical chamber contains endothelial cells that communicate across 3µm pores with
metastatic cancer cells in the central chamber. Outlet ports where perfusate from the outer
compartment (F) and central compartments are collected (D).
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Figure 5.2: Re-engineering of the BTB microfluidic device to allow for real-time TEER
measurements

A schematic (Left) and an example set-up of the device for TEER measurement is shown
(right). Silver chloride electrodes are threaded through Tygon tubing attached to the
electrode ports. An electrochemical workstation is interfaced using clips.
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Port A to Port B
Volume (same
as E to F) =
0.806 ul
Port C to Port D
Volume = 1.795
ul

The volume of
the arc of the
apical chamber
= 0.058 uL

Total device
volume
= 3.409 ul

Figure 5.3: Port volumes of the current microfluidic device

Inlet ports for the apical chambers (A,E), basolateral chamber (C) and outlet ports for the
apical chambers (B,F) and basolateral chamber (D) are depicted with the respected
volumes described.
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Figure 5.4: Proposed redesign for increased recovery port volumes of the microfluidic
device

A CAD layout of the design and parameters for the optimized BTB microfluidic device
with the proposed redesign schematic of the BTB microfluidic device (Left) and the
process of microfabrication of the porous architecture (Right).
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Figure 5.5: Tumor cell extravasation
Tumor cell extravasation across a microfluidic device.
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Figure 5.6: Isolation of different cells of varying metastatic potential

Concept of multi-cellular architectures in the central chamber which can separate
invading cells by degree of migration (top). Concept of multiple outlets from the central
chamber to capture the different cell populations.
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Technical experience in working with mammalian, cancer, and stem cell lines.

•

Extensive experience in the following imaging techniques:
o Confocal, brightfield, fluorescence, multiphoton, inverted live cell
confocal, dual upright microscope and stereoscope, laser microdisection
scope, and transmission electron microscopes, as well as Nikon NIS
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elements and analysis, 3i SlideBook, and other imaging analysis software
packages.

•

Extensive experience in chemotherapy, specifically in brain metastases of breast
cancer.

•

Extensive experience with in vitro models (transwells, BBB chip models) and in
vivo mouse models to study the movement and efficacy of chemotherapy in the
treatment of brain metastases of breast cancer.

•

Extensive expertise in radiopharmaceutical handling and autoradiography to
determine drug concentration or distribution.

•

Experience with in-situ brain perfusion kinetics and in vitro BBB model kinetics.

•

Demonstrated strong leadership in managing various research projects within the
lab and among various coworkers.

PROFESSIONAL ACTIVITIES

PROFESSIONAL ORGANIZATION MEMBERSHIPS

•

American Association for Cancer Research, AACR (2015 – current)

•

American Association of Pharmaceutical Scientists, AAPS (2014 – current)
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PROFESSIONAL PUBLICATIONS – PEER REVIEWED

Terrell-Hall TB, Ammer AG, Griffith JIG, and Lockman PR. (2016) Permeability
Across the Blood-Brain Barrier and Blood-Tumor Barrier; A Novel In vitro Model on a
Chip. Cancer Growth Metastasis. Submitted.

Terrell-Hall TB, Amrawey FE, Nounou MI, and Lockman PR. (2016) Trastuzumab
efficacy in an in vivo and in vitro model of brain metastases of breast cancer. Fluids
Barriers CNS. Submitted.

Bohn KA, Adkins, CE, Mittapalli RK, Terrell-Hall TB, Mohammad AS, Shah N, Dolan
EL, Nounou MI, Lockman PR. (2016) Semi-automated rapid quantification of brain
vessel density utilizing fluorescent microscopy. J Neurosci Methods. 1;270:124-31.

Adkins CE, Mohammad AS, Terrell-Hall TB, Dolan EL, Shah N, Sechrest E, Griffith J,
Lockman PR. (2016) Characterization of passive permeability at the blood-tumor barrier
in five preclinical models of brain metastases of breast cancer. Clin Exp Metastsis.
33(4):373-83.

Adkins CE, Nounou MI, Hye T, Mohammad AS, Terrell-Hall T, Mohan NK, Eldon
MA, Hoch U, Lockman PR. (2015) NKTR-102 Efficacy versus irinotecan in a mouse
model of brain metastases of breast cancer. BMC Cancer. 15:685
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Adkins CE, Nounou MI, Mittapalli RK, Terrell-Hall TB, Mohammad AS, Jagannathan
R, Lockman PR. (2015) A novel preclinical method to quantitatively evaluate early-stage
metastatic events at the murine blood-brain barrier. Cancer Prev Res. 8(1):68-76.

El-Habashy SE, Nazief AM, Adkins CE, Wen MM, El-Kamel AH, Hamdan AM, Hanafy
AS, Terrell TO, Mohammad AS, Lockman PR, Nounou MI. (2014) Novel treatment
strategies for brain tumors and metastases. Pharm Pat Anal. 3(3):279-96.

Adkins CE, Mittapalli RK, Manda VK, Nounou MI, Mohammad AS, Terrell TB, Celik
Y, Groethe TR, Lockman JA, Lockman PR. (2013) P-glycoprotein mediated efflux limits
substrate and drug uptake in a preclinical brain metastases of breast cancer model.
Frontiers in Pharmacology. 4:136.

Mittapalli RK, Liu X, Adkins CE, Nounou MI, Bohn KA, Terrell TB, Qhattal HS,
Geldenhuys WJ, Palmieri D, Steeg PS, Smith QR, Lockman PR. (2013) Nanoparticle
Paclitaxel Conjugates Prolong Overall Survival in a Preclinical Brain Metastases of
Breast Cancer Model. Mol Canc Ther. 12(11): 2389-99.

BOOK CHAPTERS
Nounou MI, Adkins CE, Terrell TB, Bohn KA, Lockman PR. 2012. Drug Delivery to
the CNS: Breaking Down the Barrier. In Book “Drug Delivery” (Edited by. AK Mitra)
Jones and Bartlet Learning, Burlington MA. ISBN - 10: 1284025683, ISBN-13: 9781284025682, 2014.
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PUBLISHED ABSTRACTS
Mohammad AS, Adkins CE, Terrell-Hall TB, Sechrest, ER, Dolan E, Griffith J, Shah N,
Jagannatha R, Lockman PR. “Demonstration of casual relationship between blood-tumor
barrier permeability changes and chemotherapeutic uptake and effect in brain micrometastases of breast cancer.” AACR Annual Meeting. New Orleans, LA. 2016.

Adkins CE, Mohammad AS, Dolan E, Griffith J, Terrell-Hall T, Lockman PR.
“Inhibition of TGFß to prevent brain metastases of breast cancer.” AACR Annual
Meeting. New Orleans, LA. 2016.

Bohn K, Terrell-Hall TB, Lockman PR, et al. “Vascular remodeling is associated with
increased permeability of experimental brain metastases of breast cancer.” AACR Annual
Meeting. Philadelphia, PA. 2015.

Bohn K, Sechrest ER, Adkins CE, Mittapalli RK, Nounou MI, Terrell-Hall TB,
Mohammad AS, Lockman PR. “Inhibition of VEGF and angiopoietin-2 to reduce brain
metastases of breast cancer burden.” AACR Annual Meeting. Philadelphia, PA. 2015.
Mohammad AS, Adkins CE, Mittapalli RK, Terrell-Hall TB, Nounou MI, Lockman PR.
“Characterization of changes in passive permeability and drug uptake at the blood-tumor
barrier in four preclinical models of brain metastases of breast cancer.” AACR Annual
Meeting. Philadelphia, PA. 2015.
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Nounou MI, Adkins CE, Terrell TO, Mohamed A, Vitalis T, Gabathuler R, and
Lockman PR. "Anti-cancer antibody trastuzumab-melanotransferrin conjugate (BT2111)
for the treatment of metastatic HER2+ breast cancer tumors in the brain: An in vivo
study"; Poster Presentation, The American Association of Cancer Research (AACR)
annual meeting, San Diego, CA, USA, April 5-9, 2014.

Nounou MI, Hoch U, Adkins CE, Terrell TO, Villalba H, Eldon ME, and Lockman PR.
"Etirinotecan pegol accumulates in breast cancer brain metastases and prolongs survival
in an experimental model of brain metastases of human triple negative breast cancer";
Poster Presentation, The American Association of Cancer Research (AACR) annual
meeting, San Diego, CA, USA, April 5-9, 2014.

Nounou MI, Adkins CE, Terrell TB, Villalba H, and Lockman PR. "Characterization of
changes in passive permeability and drug uptake at the blood-tumor barrier in four
preclinical models of brain metastases of breast cancer"; Poster Presentation, The
American Association of Pharmaceutical Scientists (AAPS) annual meeting, San
Antonio, TX, USA, November 10-14, 2013.

Hoch U, Nounou MI, Adkins CE, Terrell TB, Villalba H, Eldon ME, Perez E, and
Lockman PR. "Etirinotecan pegol prolongs survival in an experimental model of brain
metastasis of human triple negative breast cancer"; Poster Presentation, European Cancer
Congress 2013 (ECCO-ESMO-ESTRO), Amsterdam, Netherlands, September 27thOctober 1st 2013.
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Gabathuler R, Vitalis TZ, Nounou MI, Iqbal U, Moreno M, Adkins CE, Terrell TO,
Smith QR, Jefferies WA, and Lockman PR; " BT2111, a New Anti-Cancer Agent
composed of trastuzumab and Transcend a Vector for Brain Delivery for the Treatment
of Metastatic Her2+ Breast Cancer"; Poster Presentation, AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA,
USA, October 19-23, 2013.

Hoch U, Nounou M, Adkins CE, Terrell TB, Villalba H, Eldon E, Lockman PR.
“Etirinotecan pegol prolongs survival in an experimental model of brain metastasis of
human triple negative breast cancer”. 17th ECCO – 38th ESMO, Amsterdam,
Netherlands. 2013.

Nounou MI, Bohn KA, Adkins CE, Terrell TB, Bansal A, Smith QR, Lockman PR.
“Effect of Bevacizumab on vascular permeability and drug uptake in brain metastases of
breast cancer”. Annual Meeting of the American Association of Pharmaceutical
Scientists, Chicago, IL 2012.
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